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1. EXECUTIVE SUMMARY 
The death of more than 6 million people in the world from HIV/AIDS, malaria and 
tuberculosis (TB) each year constitutes a global crisis. In 2000, the European 
Commission (EC) redefined its role and accelerated its response in a coherent and 
comprehensive framework.1 In 2001, the EC adopted its Programme for Action2 
(PfA) based on this framework, which defined key actions to accelerate the impact, 
affordability and research and development of new tools. It is now an appropriate 
time to assess the progress made, build on achievements and face new challenges. 
This progress report illustrates that the main achievement under the area for action on 
accelerating impact has been a four-fold increase in EC resources allocated 
specifically to confronting the three diseases, with an annual average of €259.02 
million programmed for 2003-2006 as compared to the €59.32 million annual 
average committed for 1994-2002 (including a significant increase in research 
funds). In the action on affordability, there has been a reduction of up to 98% in the 
price of some key pharmaceutical products in developing countries. Under the 
research and development action, a key achievement has been the establishment of 
the European and Developing Countries Clinical Trials Partnership, which focuses 
on clinical trials for the development of new interventions confronting the three 
diseases, especially in sub-Saharan Africa. The active EC role in terms of leadership, 
coordinating positions and mobilising resources among the EU Member States and 
other donors is a key achievement under the partnership action. Examples of this 
include a strong European voice in the Global Fund to Fight HIV/AIDS, TB and 
malaria (to which the EU contributes more than half of the budget), and in 
international fora on key issues such as Trade-Related Aspects of Intellectual 
Property Rights and sexual and reproductive health and rights. 
The main outstanding challenges include how to increase the prioritisation of, and 
resources to, health and social services in third countries; how to boost ailing health 
infrastructure and overburdened human capacities, especially in the current context 
of brain drain; how to support regulatory capacity in third countries; how to further 
increase affordability of key pharmaceutical products, and improve access to 
pharmaceutical products in general; how to develop new tools to confront the three 
diseases; and how to continue coordination with partners in third countries, civil 
society and the private sector. New challenges include how to maintain coherence 
and harmony in an increasingly complex and divergent global institutional set-up, 
and how to respond to the evolving epidemiology, geography and demography of the 
diseases in the context of an enlarged EU. 
This progress report illustrates how the policy framework and the PfA remain valid. 
The overall framework of poverty reduction is still the main focus, especially in the 
                                                 
1 Accelerated Action Targeted at Major Communicable Diseases within the Context of Poverty Reduction 
(COM(2000) 585) 
2 Programme for Action on Communicable Diseases in the Context of Poverty Reduction (COM(2001) 
96) 
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context of achieving the Millennium Development Goals by 2015. The focus on the 
three diseases, with an appropriate and comprehensive policy mix to confront the 
diseases, including prevention, treatment and care, remains valid. EC action at both 
country and global levels should continue and expand, given that simultaneous 
actions reinforce each other and allow for increased effectiveness. The synergy and 
coherence of different policy areas within the EC should be further strengthened, in 
order to push the momentum forward, reinforce commitment and shape key actions 
for the future. An updated and comprehensive policy framework for confronting 
HIV/AIDS, malaria and TB globally will be presented in an EC Communication to 
follow this progress report. 
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2. INTRODUCTION 
Substantial progress has been made since the groundbreaking European Commission 
High-Level Round Table on HIV/AIDS, malaria and tuberculosis took place in 
September 2000, and the adoption of the policy framework for a comprehensive and 
accelerated approach to confront HIV/AIDS, malaria and tuberculosis (TB). It is now 
time to take stock, reflect on progress made and new challenges, and to accelerate 
and readjust actions where needed. The coherent and comprehensive policy 
framework remains valid in the context of the Millennium Development Goals 
(MDGs) and the overarching objective of poverty reduction. The need to focus on 
HIV/AIDS, malaria and TB is clearly reflected in Millennium Development Goal 
(MDG) 6 – “Combat HIV/AIDS, malaria and other diseases” which includes 
associated targets and indicators – and other inter-linking MDGs on health and 
poverty.3 Confronting the three diseases remains high on the agenda for EU 
Presidencies, both current (the Netherlands) and future (Luxembourg, the UK, 
Austria and Finland). 
However, despite efforts made and resources allocated, the number of people 
affected, infected and dying from HIV/AIDS, malaria and TB continues to rise. In 
2003, almost 3 million people died of HIV/AIDS; this is rapidly becoming the worst 
infectious disease catastrophe in recorded history, surpassing in absolute numbers the 
bubonic plague of the fourteenth century and the influenza epidemic of 1917, each of 
which killed around 20 million people. Malaria kills more than one million people 
every year, including an African child every 30 seconds.4 TB kills about 2 million 
people every year.5 
2.1. The EU policy framework and programme for action on HIV/AIDS, malaria 
and tuberculosis 
A comprehensive policy framework: HIV/AIDS, malaria and TB collectively 
undermine global health, poverty reduction and human security. In 2000, the 
European Commission (EC) redefined its role and accelerated its response to the 
global emergency in a coherent and comprehensive framework on Accelerated 
Action targeted at major communicable diseases within the context of poverty 
reduction.
6 This Communication was discussed at a High-Level Round Table with a 
large number of stakeholders, held in Brussels in September 2000. 
Cooperation, coherence and synergy: In the policy framework, the EC highlighted 
the value and importance of harnessing several key policy areas and instruments to 
work towards a common goal. Different policy areas within the EC redirected some 
                                                 
3 MDG Target (7): Have halted by 2015, and begun to reverse, the spread of HIV/AIDS. 
MDG Target (8): Have halted by 2015, and begun to reverse, the incidence of malaria and other major 
diseases. Please see web-page http://www.un.org/milleniumgoals for further information. 
4 WHO “What is Malaria”, from www.rbm.who.int 
5 WHO “Basic Facts on TB”, from www.stoptb.org 
6 Accelerated Action Targeted at Major Communicable Diseases within the Context of Poverty 
Reduction (COM(2000) 585) 
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of their activities to confront the three diseases. It was recognised that the EC has a 
unique mandate to coherently address a range of development, humanitarian aid, 
trade, research, enterprise, health and education issues. This range of competences 
and instruments provided the potential for greater synergy across these policy areas. 
Description of the Programme for Action: To formulate actions for 2001-2006 
within the policy framework, the EC adopted a Programme for Action on 
Communicable Diseases in the Context of Poverty Reduction (COM(2001) 96). 
Council and Parliament welcomed the Programme for Action (PfA) in their 
resolutions of 14 May 2001 and 4 October 2001 respectively (refer to Annex 1 for 
further policy declarations and resolutions of relevance to the policy framework and 
the PfA). The PfA was later assessed and updated in a progress report adopted by the 
EC in February 2003.7 
The vision of the policy framework is to accelerate the response to confront the three 
diseases. This requires intensified support to strengthen social sectors beyond the 
health sector to include enabling sectors such as education, transport and food 
security, and cross-cutting issues regarding human resources. The PfA focuses on 
three inter-related areas for action: to increase the impact of existing interventions, 
to increase the affordability of key pharmaceutical products, and to encourage 
research in and development of specific global public goods. 
These actions are inter-related and synergistic, with each having a multiplying effect 
with a larger cumulative impact – one example being the interrelationship that exists 
between affordability of pharmaceutical products, impact through existing 
interventions and incentives for further research and development of new 
pharmaceutical products. Results are achieved by acting at two levels – through 
accelerating and increasing resource allocation at country level, and through 
advocating and adopting key policies and action at global level. 
The PfA also reflects EC policy on sexual and reproductive health and rights,8 
maintaining the commitments made at the International Conference on Population 
and Development (ICPD) in Cairo, 1994.9 The PfA is part of the overall EC 
Development Policy, which highlights poverty reduction as a priority goal.10 
                                                 
7 Update on the EC Programme for Action: Accelerated Action on HIV/AIDS, Malaria and Tuberculosis 
in the Context of Poverty Reduction – Outstanding Policy Issues and Future Challenges (COM(2003) 
93) 
8 Regulation (EC) No 1567/2003 of the European Parliament and of the Council on Aid for Policies and 
Actions on Reproductive and Sexual Health and Rights in Developing Countries and Accelerated action 
targeted at major communicable diseases within the context of poverty reduction, COM(2000) 585. 
9 http://www.un.org/popin/icpd2.htm 
10 EC development policy statement by the Commission and Council (10 November 2000). The EC’s 
Health, AIDS and Population policy, as set out in the Communication on Health and Poverty Reduction 
(2002), also clearly defines this poverty reduction goal. Health and Poverty Reduction in Developing 
Countries (COM(2002) 129) 
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The PfA is implemented using a range of instruments: geographic budget lines,11 
horizontal or thematic budget lines,12 and the EU Framework Programme for 
Research and Technological Development (FP (RTD)). 
2.2. The comprehensive policy mix needed to confront the three diseases 
The PfA calls for new partnerships to strengthen policy advocacy and political 
dialogue. The PfA also calls for a comprehensive policy framework, taking an 
appropriate mix of innovative, more efficient and less costly disease responses in 
prevention, treatment and care. An appropriate mix depends on the nature of the 
disease, capacities and resources available within the country and region; but most 
crucially, it depends on proven best practice. 
HIV/AIDS: The majority of HIV infections occur through sexual contact, and are 
preventable. The effectiveness of condom use in preventing transmission of 
HIV/AIDS through sexual contact is a proven fact. The knowledge and ability to 
openly discuss and negotiate an informed choice is important, and is something that 
many people – especially women – lack. The use of condoms by non-regular partners 
remains very low for several reasons, including lack of access. Gender inequalities 
also mean that many women in developing countries are deprived of negotiating 
skills to enable them to protect their own lives and the wellbeing of their families. 
Condoms are the only current tool available for protection from sexual transmission 
of HIV/AIDS, but they are controlled by men. The rapid development and 
introduction of effective microbicides is therefore crucial for women in developing 
countries and elsewhere in order for them to protect themselves against HIV/AIDS 
transmission. A high proportion of HIV/AIDS transmission occurs through injecting 
drug use. Harm reduction, through needle exchange and/or substitution therapies, is 
proven to reduce the transmission of HIV/AIDS through injecting drug use. 
However, access to harm reduction services is limited in many countries where it is 
most needed. 
The recent price reduction in anti-retrovirals (ARVs) for treatment of HIV/AIDS has 
resulted in an increase in the number of people treated in developing countries. 
HIV/AIDS could be a chronic disease controlled by drugs instead of a life sentence, 
but only 2% of those in developing countries who need ARVs have access to it (and 
only 1% in Africa). With ARV therapy now being a significant element of an 
increasing number of national programmes, mobilising sufficient resources to 
achieve a balanced response between prevention, treatment and care in national 
HIV/AIDS strategies is becoming an increasing challenge. The provision of ARV 
therapy is also placing an increasing challenge on already ailing health 
infrastructures and overburdened health staff. 
                                                 
11 These are resources to Africa, Caribbean and Pacific (ACP) countries from the European Development 
Fund (EDF), including regional and intra-ACP; Asia and Latin America (ALA); Mediterranean 
(MEDA); and Eastern Europe and Central Asia (TACIS). 
12 The relevant ones being Aid to Fight Poverty Diseases, Co-funding with NGOs, Aid for Policies and 
Actions on Reproductive and Sexual Health and Connected Rights, and Humanitarian Aid. 
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Fixed-dose combinations (FDCs), which combine multiple drugs in one pill, are 
easier to administer and use than the cocktail of drugs which imply taking 3 times 
more pills per day. FDCs are mainly produced by generic manufacturers. There are 
still no FDCs for paediatric formulations of ARVs. 
TB: A person with HIV/AIDS who develops active TB has a life expectancy of just a 
few weeks or months. Up to half of those with HIV/AIDS in developing countries 
will die of TB. For those on the lengthy waiting list to receive antiretroviral treatment 
for AIDS, having access to TB treatment is a matter of life and death. The cost of the 
pharmaceutical products for a full course treatment under the DOTS (directly-
observed therapy short-course) scheme has been reduced to US$10, and TB can be 
successfully treated and life expectancy extended by several years. It is a challenge 
for health systems to effectively administer DOTS given the complication and length 
of treatment, and the improper use of TB drugs has resulted in a growing trend of 
multi-drug resistant TB. In addition, TB diagnostics tools are outdated and difficult 
to use. Innovative initiatives are needed to increase the detection of tuberculosis and 
compliance with treatment, particularly amongst the poorest. 
Malaria: Malaria can be prevented using vector-control (e.g. drainage of swamps 
and insecticide spraying of houses), or transmission to humans can be prevented in 
many areas using insecticide-treated bednets (ITNs)13. The development of long-
lasting ITNs (which last five years, the time span that newborn children are most 
vulnerable to malaria) offers new potential for confronting the disease. At the current 
price of $5 per net, long-lasting ITNs are already more cost-effective than 
conventionally treated nets. Treating pregnant women with anti-malarials is 
particularly important because of the potentially harmful effects the disease can have 
on their children and themselves. Treatment with new drugs, among them 
artemisinin-based combination therapy (ACT) is needed because of increasing 
resistance to traditionally used malaria medicines like chloroquine. However, ACTs 
are significantly more expensive than traditionally used malaria medicines. 
2.3. Objective of the document 
Why this progress report? The policy framework and the PfA are major initiatives 
for confronting HIV/AIDS, malaria and TB. The EC has seen significant 
achievements in confronting the three diseases over the past few years. Globally, 
there has also been an increase in the amount of resources channelled towards 
HIV/AIDS, malaria and TB. A large number of new players have joined the scene 
and changed the global institutional architecture. Now is therefore an appropriate 
time to assess progress made on the PfA, to build on these achievements and face 
new challenges. 
This progress report outlines implementation so far on each of the three PfA areas for 
action – impact, affordability, and research and development. The EC’s participation 
                                                 
13 By 2003, 18 out of the 40 malaria-endemic countries in Africa with country strategy plans for rolling 
back malaria had developed strategic plans that included increasing access to ITNs. Twenty-five 
African countries successfully applied for funding in the second round of Global Fund applications 
(from Africa Malaria Report 2003, http://www.rbm.who.int/amd2003/amr2003/ch2.htm  
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in global partnerships is also discussed. The report integrates and builds on key 
findings of the 2003 progress report. 
How will this progress report be used? This progress report provides input into an 
EC consultation where outstanding and new challenges are being analysed to define 
key actions for the EC and the EU. Later this year, the EC will continue its 
discussions with Council and Parliament on the Financial Perspectives (period 2007-
2013) for the enlarged EU. At the same time, discussions are ongoing on the new 
instruments to be adopted for EC external action. The EC will also continue its 
dialogue with EU Member States and stakeholders regarding the updating of the EC 
Development Policy. The outcomes of these discussions are of primary importance 
given that one of the main challenges currently faced by the EC is how to ensure 
increased and sustainable financial commitments to the Millennium Development 
Goals, including MDG 6. This progress report will also provide timely input into the 
report on EU progress towards the MDGs, which is currently being prepared for 
presentation at the upcoming UN summit in September 2005. 
3. ACHIEVEMENTS OF THE POLICY FRAMEWORK AND THE PFA 
3.1. Impact 
Rationale for action: Increased and accelerated efforts are needed both at country 
and at global level to confront the three diseases using existing interventions, while 
at the same time strengthening essential services and systems. 
3.1.1. Optimising the impact of Health, AIDS and Population interventions targeted at the 
three communicable diseases and poverty reduction 
The PfA calls for increased funding, quick disbursement and accelerated action to 
provide wider access to prevention, treatment and care, especially for the poor, to 
confront the three diseases. In general, there has been no increase in resources 
allocated to health since the PfA. However, there has been an accelerated 
disbursement of funds to health through country and macroeconomic budget support. 
A major achievement has been the creation of a new and innovative horizontal 
budget line to confront the three diseases specifically. There has also been an 
increase in resource allocation through regional and horizontal budget lines over time 
to confront the three diseases. 
Macroeconomic budget support: Macroeconomic budget support is EC support for 
a country’s budget through a geographic budget line. A varying proportion of the 
macroeconomic budget support contributes to improved health outcomes in each 
country, depending on the Country Strategy Papers (CSPs) and national prioritisation 
of health. As Table 1 below illustrates, €40.42 million per year is estimated to have 
been channelled to the health sector in European Development Fund (EDF) countries 
 EN 13   EN 
from macroeconomic budget support.14 Whilst this figure seems low compared to the 
annual EC investment through budget support, it reflects the fact that national budget 
allocations to health are low in many countries, and increased national allocations to 
health, in line with poverty reduction strategy objectives, will be needed before there 
can be a greater allocation of EC macroeconomic budget support to the health sector. 
It is difficult to compare this figure to previous macroeconomic budget support going 
to health. 
It is also difficult to see the health outcomes due to this financial allocation. In 
countries where the EC provides macroeconomic budget support, health process and 
output indicators are included to assess overall country performance, especially 
relating to the MDGs (e.g. HIV prevalence, attendance of skilled birth attendants, 
immunisation coverage). The inclusion of such indicators can contribute to the 
strengthening of in-country budget allocations or country programmes on the three 
diseases, assuming that agreement on targets reflects agreement on national priorities 
for investment. All countries, regardless of their choice of focal sector, are advised to 
include the MDG-related outcome indicator – “HIV prevalence among 15-24 year-
old pregnant women” in their monitoring and reporting systems. In the 2004 mid-
term review of all the CSPs for the EC cooperation partners in ACP countries, 32 out 
of the 68 countries for which the data has been analysed used exactly this indicator in 
their core list.15 23 countries included a different indicator on HIV/AIDS, while 13 
did not use any HIV/AIDS indicator at all. Analysis of this outcome indicator 
remains limited, and cannot yet illustrate trends over time. 
Specific health sector support: As Table 1 below illustrates, health sector support 
through country programming has decreased by a third from a €393 million annual 
average (commitments 1998-200216) to a €246.6 million annual average 
(programmed support 2003-200617). Although geographic support for health has 
decreased when comparing 1998-2002 and 2003-2006, there has been accelerated 
expenditure of resources through faster disbursement of money to countries This 
reflects a general increase in the EC disbursement rate in development coopertaion 
which includes a 47% increase in payments since 2000.18. 
The primary mechanism for EC partnership at country level are the Country Strategy 
Papers (CSPs), and policy dialogue around Poverty Reduction Strategy Papers 
(PRSPs). Countries have been encouraged to focus on two sectors in the CSP.19 In 
the period 2002-2006, the EC provides specific funding for health for only 27 out of 
106 countries. Reasons for countries not choosing health as a focal sector may 
include the traditional expertise of the EC being in other sectors (e.g. transport), the 
lack of health expertise in EC delegations able and willing to advise and argue for 
                                                 
14 The proportion of the EC macroeconomic support allocated to the health sector is calculated using the 
percentage of the government’s budget commitment to health as outlined in the World Health Report 
2004. 
15 Only 55 of the total 76 had data available 
16 Source: Population and development mid-term evaluation 
17 Source: Country Strategy Papers 
18 http://europa.eu.int/comm/europeaid/reports/reform_def_en.pdf 
19 The EC decided to focus on only two sectors so that it does not spread its support too thinly. 
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health support in discussions with the government, and – in many countries – the 
weak position of the Ministry of Health (relative to other Ministries) in the policy 
dialogue. However, participation in sector support programmes makes for more 
intense dialogue on health policies and how to improve them and increase support for 
systems. 
Table 1: EC support for health from geographic line items (1998-2002 
compared to 2003-2006) 
Instruments Annual average 1998-2002 
(commitments, from Population and 
Development mid-term review) 
Annual average 2003-2006 
(programmed support, from Country 
Strategy Papers) 
Macroeconomic budget support 
estimated input to health 
Difficult to calculate from DAC 
records and consolidated developing 
countries government allocation to 
health, 2000-2001 
€40.42 million (EDF data only, 
MEDA countries not included) 
Specific health sector support 
through country programming 
€393 million €246.6 million 
In contrast to the decreases in specific health sector support, the amount of money 
specifically allocated to confront the three diseases has increased over time. As 
illustrated in Table 2 below, the EC programmed €259.02 million per year to 
confront the three diseases (annual average 2003-2006), a four-fold increase from the 
annual average of €59.32 million committed between 1994-2002. The greatest 
amount of increase has come from the Aid for Poverty-Related Diseases budget line 
(which saw an 8.7-fold increase), followed by an increased allocation to the three 
diseases through the regional budget line (an almost 5-fold increase), and an increase 
by 4 times in the FP (RTD) allocation to HIV/AIDS, malaria and TB. 
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Table 2: EC financial commitments/programmed support specifically to confronting 
HIV/AIDS, malaria and TB (annual averages by instrument, in € million)
20
 
Instruments Annual average (€ million) 
1994-2002 
Annual average (€ million) 
2003-2006 
Geographic budget lines Regional21 11.92 56.76 
Horizontal/thematic 
budget lines 
Aid for Poverty-Related 
Diseases22 
10.10 88.25 
 Humanitarian Aid 1.60 1.50 
 NGO co-financing 12.60 12.51 
Framework Programme 
for Research and 
Technological 
Development 
4th, 5th and 6th FP 
(RTD) 
23.10 100.00 
TOTAL  59.32 259.02 
Regional support: Support specifically for the three diseases has been channelled 
through regional or intra-ACP funds. As Table 2 illustrates, there was an increase 
from €11.92 million (average annual commitment, 1994-2002) to €56.76 million 
(average annual programmed, 2003-2006) to confront the three diseases. Another 
significant achievement since the PfA was adopted has been the more flexible use of 
this instrument, which allows for increased resources at country level, and for 
support for innovative partnerships. For example, part of the intra-ACP funds are 
used to support the Global Fund;23 to support pharmaceutical policy development in 
countries (with the World Health Organization); health information system 
development through the Health Metrics Network with WHO; and to develop 
malaria vaccine trial capacities in Africa through AMANET (African Malaria 
Network Trust). This EC-funded project (for €7 million) aims to strengthen a pan-
African network that will enhance the human and institutional capacity needed for 
clinical development and evaluation of malaria vaccines. AMANET, which is the 
only registered trust composed of African public health and research institutions, will 
                                                 
20 Sources: (1994-2002): Population and Development Evaluation, see 
http://europa.eu.int/comm/europeaid/evaluation/evinfo/sector/951649_ev.htm 
(2003-2006): Programming data from DG Development, see 
http://europa.eu.int/comm/development/body/theme/human_social/pol_health1_en.htm, updated from 
brochure http://europa.eu.int/comm/development/body/publications/descript/pub7_10_en.cfm 
Breakdown by diseases from Global Fund, see progress reports by diseases: 
http://www.theglobalfund.org/en/funds_raised/reports/ 
21 Calculated from regional programmes and intra-ACP programmes 
22 Before 2003, money for HIV/AIDS came from the AIDS and Population budget line. Breakdown after 
2003 is indicative, pending first selection of proposals from 2003 call. 
23 Established in 2002, the purpose of the Global Fund to Fight AIDS, TB and Malaria is to attract and 
disburse resources to prevent and treat AIDS, TB and malaria. www.theglobalfund.org 
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implement the project. The project will result in an operational network of efficacy 
evaluation centres in Burkina Faso, Mozambique and Tanzania, with properly skilled 
staff through short, long and on-site training. Four malaria candidate vaccines will 
undergo clinical trials under internationally accepted good clinical practice and 
ethical standards. 
Another part of the intra-ACP budget is used to ensure continued reproductive health 
services in countries through support for the United Nations Population Fund 
(UNFPA) and the International Planned Parenthood Federation (IPPF). This has been 
done in response to the withdrawal of US funding following the US’s re-introduction 
of the Mexico City policy (or ‘global gag rule’), halting funding of organisations 
providing legal abortion services, counselling and referral for abortion, or lobbying 
to make abortion legal or more available in their own country. 
Aid for Poverty-Related Diseases: One of the main achievements of the past three 
years has been the adoption of the budget line on Aid for Poverty-Related Diseases24 
in 2003 as a new instrument to implement the PfA with a financial framework of 
€351 million (2003-2006). This new instrument supports innovative initiatives and 
targeted actions that can later be scaled up through other financial instruments.  
The new instrument has been a catalyst for action to confront the three diseases. The 
EC has harnessed non-development resources into this budget line and thus focused 
additional resources into development priorities. The budget line has provided for 
flexibility and additional impact beyond geographic programming. While geographic 
programmes address health interventions at national or regional level, this budget 
line also ensures EU action, impact and visibility at global level, while supporting 
demand driven proposals put forward by various in-country stakeholders. It 
contributes resources to the Global Fund;25 to community preparedness initiatives for 
an AIDS vaccine through the International Aids Vaccine Initiative (IAVI);26 to the 
International Partnership for Microbicides (IPM)27 for microbicide development; and 
for second generation surveillance on HIV/AIDS through WHO/UNAIDS. In the 
calls for proposals for 2005 and 2006, EDCTP clinical trials sites proposals are 
encouraged. 
One example of country impact from this thematic budget line is an EC-funded 
programme on HIV/AIDS treatment in Senegal, which has proven that highly active 
anti-retroviral therapy can successfully be administered in a resource-poor setting. 
The programme has set a precedent for the establishment of a national treatment 
programme planning to treat 7,000 people by 2006. 
                                                 
24 This Regulation (EC) No 1568/2003 of the European Parliament and of Council was adopted on 16 
June 2003. 
25 €6.67 million was given to the Global Fund prior to 2003 
26 The International AIDS Vaccine Initiative (IAVI) was created in 1996 and is working to ensure the 
development of safe, effective, accessible and preventive HIV vaccines for use throughout the world. 
www.iavi.org 
27 The International Partnership for Microbicides (IPM) was established in 2002 to accelerate the 
discovery, development and accessibility of microbicides to prevent transmission of HIV. 
http://www.ipm-microbicides.org/ 
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Other horizontal or thematic budget lines: The Sexual and Reproductive Health 
and Rights, NGO Co-financing and Humanitarian Aid budget lines are partly used to 
confront the three diseases. The Regulation on Aid for Policies and Actions on 
Reproductive and Sexual Health and Rights in Developing Countries28 was adopted 
in 2003, and includes financial assistance to programmes on the prevention of sexual 
and mother-to-child transmission of HIV/AIDS, and initiatives to reduce malaria 
burden during pregnancy and in newborns. It sets an overall financial framework of 
€73.95 million for implementation during the period 2003-200629 (not included in 
Table 2). 
One example of a successful EC-supported NGO Co-financing project is in Nepal, 
where the EC has contributed €1.9 million to a €5 million multi-NGO TB and 
leprosy project. This project provides cost-effective health education, early detection 
and treatment of TB, with 300,000 outpatient beneficiaries and 20,000 treated 
patients. An example of a successful EC-funded programme from the Humanitarian 
Aid budget line is the EC Humanitarian Aid Office’s action in Burundi during the 
2001 malaria epidemic, and since then with the post-epidemic response. 
EC and the Global Fund – support through flexible use of several budget lines 
and EC leadership 
An important EC achievement since 2001 has been the establishment of the Global 
Fund to Fight AIDS, TB and malaria. The EC actively supported the early Global 
Fund transitional working group in Brussels 2001 and continues to be a key partner 
working closely together with other Board members and the Global Fund Secretariat. 
The EC has played a leadership role in preparing cutting-edge policies through active 
participation as a member of the Board and in several of the working committees 
advising the Board. 
As the second largest individual donor, the EC has contributed more than 18% of the 
total Global Fund budget in 2004 and provides longer-term, predictable financing. 
The EC has committed €460.5 million from 2001 through 2006 – half from the EDF 
and half from the EC budget.30 Europe (EC and EU Member States) is now the 
largest donor, having committed more than half of the total budget for the Global 
Fund (€2.4 billion out of the total €4.6 billion). The financial support from Europe 
comes fully untied (refer to Annex 2 for details on EU Member States financial 
contributions to the Global Fund). 
                                                 
28 Regulation (EC) 1567/2003 of the European Parliament and of the Council on aid for policies and 
actions on reproductive and sexual health and rights in developing countries 
29 The new horizontal budget line replaced two budget lines on HIV/AIDS-related operations in 
developing countries (AIDS and Population, and Reproductive Health). 
30 Through intra-ACP funds and on the budget line linked to the Regulation on aid to fight poverty 
diseases (HIV/AIDS, tuberculosis and malaria) in developing countries 
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The Global Fund to Fight AIDS, TB and Malaria  
The Global Fund is an innovative and accountable financing mechanism, which 
raises, manages and disburses resources quickly to beneficiary programmes based on 
national plans and priorities, including PRSPs and sector-wide approaches (SWAps). 
Global Fund programmes are developed in an inclusive and participatory process at 
country level through Country Coordinating Mechanisms (CCMs) and evaluated by 
an independent technical review panel.  
The Global Fund is an effective and innovative way of making funds available to 
confront the three diseases at country level. Its flexibility allows for the channelling 
of resources to countries which may previously not have received EC funding for the 
three diseases, health or macroeconomic budget support through geographic 
instruments. 
The results of the Global Fund include: 
• An allocation of 56% of the funding to HIV/AIDS, 31% to malaria and 13% to 
TB. Approximately 70% of the funding goes to low-income countries and a 
further 26% to lower middle-income countries. Africa receives 60% of the total 
funding. 
• 51% of programme allocations is for strengthening the capacity of health systems. 
• The Global Fund has approved 310 programmes in 128 countries through four 
rounds of calls for proposals. 
• The EC has worked to ensure that the Global Fund sets up procurement policies 
which maintain quality standards and can make pharmaceutical products available 
at the lowest possible prices. Working with Global Fund procurement policies, 
countries such as Jamaica can save up to 50% of the costs of ARV treatment.31 
The EC has achieved full transparency with regard to the prices paid for 
pharmaceutical products by countries. 
By 2009, Global Fund programmes are expected to have achieved the following 
results: 
HIV/AIDS: The number of people on ARV treatment will have increased six-fold to 
almost 1.6 million. Voluntary HIV counselling and testing services for prevention 
will have been provided to 52 million people. Increased access to condoms has been 
included in approximate 70% of all the Global Fund-approved HIV/AIDS 
programmes. 
TB: 2.8 million people will have been immunised against TB (the coverage in 2000 
was 800,000). Treatment of multi-drug resistant TB will have quadrupled. And 3.5 
                                                 
31  The exact price reduction in first-line ARV treatment per person per year was from US$1,380 to $702. 
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million TB patients will have been treated as part of the internationally-
recommended TB control strategy DOTS (directly observed therapy short-course). 
Malaria: 108 million insecticide-treated malaria bednets will have been provided 
and 145 million artemisinin-based combination therapy treatments for malaria will 
have been delivered. 
Further information on the Global Fund can be obtained from www.theglobalfund.org 
The untying of aid: The untying of aid is an important measure to increase the value 
of ODA, and was identified as a key activity in the PfA. The decision was taken to 
untie aid for the first time in the PfA. The first country to benefit from untying was 
Zimbabwe, through an international tender for the provision of drugs and medical 
supplies. Drug procurement in Zimbabwe in 2002 and 2003 made under the Health 
Sector Support Programme managed to purchase drugs at prices around 40% below 
the prices estimated using the International Drug Price Indicator Guide published by 
WHO. The full untying of procurement through the Global Fund was a second major 
result of the PfA, due to pressure by the EC. This has led to significant reductions in 
the price of pharmaceutical products financed through Global Fund programmes. For 
example, Jamaica managed to reduce the cost of ARV treatment from US$1,380 to 
US$702 per patient/year. Honduras is another country which has reduced the price of 
first-line ARV from US$1,380 to US$205 per patient/year.32 
3.1.2. Strengthening of pharmaceutical policies and capacity building 
Capacity building: The PfA identified support to strengthen pharmaceutical policy 
and practice. In 2002, the EC programmed €25 million from the 9th EDF (intra-ACP 
funds) for support through WHO. This aims to enhance the capacity of ACP 
countries in various areas of pharmaceutical policy, including: the development, 
implementation, and monitoring of national drug policies; the negotiation and 
monitoring of international trade agreements on pharmaceutical products, and the 
development of supportive related legislation and regulations; the improved 
affordability and financing of essential drugs in both the public and private sectors; 
the establishment of more reliable and efficient pharmaceutical product supply 
management systems, including, where appropriate, development of regional pooled 
procurement; the strengthening of norms, standards and guidelines for the quality, 
safety and efficacy of key drugs (including the fight against counterfeit drugs); and 
training and monitoring the rational prescription and dispensing of drugs by health 
professionals. The overall objective of the programme is to close the huge gap 
between the potential that essential drugs have to offer and the reality that for 
millions of people – particularly the poor and disadvantaged – drugs are unavailable, 
unaffordable, unsafe or improperly used. 
In addition to this regional cooperation on pharmaceutical policy, the EC provides 
support through its bilateral cooperation with several African countries to the 
                                                 
32 Report on Wilton Park Conference (WP751), Scaling up Health Investments in Developing Countries: 
Lessons about what Works, 16-18 June 2004 
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development of national pharmaceutical policies (e.g. in Mozambique) and essential 
drug supply (e.g. in Zimbabwe). In Chad and Guinea, the health programmes have 
specific components on pharmaceutical policies. 
Enhanced partnerships: Developing countries need to be sure of the quality and 
safety of pharmaceutical products they intend to purchase. To support this, part of the 
€25 million EC allocation in 2002 goes to the WHO prequalification project 
(Procurement, Quality and Sourcing Project: Access to HIV/AIDS, tuberculosis and 
malaria products of acceptable quality). The WHO prequalification process assesses 
the quality, safety and efficacy of drugs submitted by participating manufacturers. It 
evaluates pharmaceutical manufacturers and products according to WHO 
recommended standards of quality and compliance with Good Manufacturing 
Practice. The project was originally set up in 2001 to give UN procurement agencies 
the choice of a range of quality drugs, which would facilitate access. Since then, the 
list has increasingly been used by other purchasing agencies and organisations as 
well as by countries. The list of pharmaceutical products pre-qualified by WHO 
includes FDCs for HIV/AIDS, malaria and TB. These are recommended by WHO 
for patients in resource-poor countries.33 However, many local production sites have 
not yet been assessed, and WHO recently removed five generic products (including 
three FDC drugs) used to treat HIV/AIDS patients from the list, referring to lack of 
evidence on bioequivalence with patented products. This leaves only three fixed-dose 
combination ARVs on the WHO list, which narrows the choice of affordable 
pharmaceutical products available for use in developing countries. 
Regulatory issues, with the EMEA and WHO: The PfA specified the need to 
enhance and improve regulatory schemes. A key achievement has been the recently 
adopted revision of the EU pharmaceutical legislation. This lays down specific 
provisions enabling the European Medicines Agency (EMEA) to give a scientific 
opinion, upon request by WHO, for the evaluation of certain medicinal products 
manufactured in the EU intended for markets outside the EU.34 These provisions 
respond to the need to protect public health and give scientific assistance to 
developing countries, while at the same time allowing rapid access to those countries 
for important new medicinal products. It should be coordinated with a gradual 
strengthening of national and regional capacities to progressively reduce dependency 
and increase ownership. 
Licensing mechanisms for pharmaceutical products outside of developing countries 
can still affect them, even more so because their own regulatory capacities are weak. 
For example, the US’s Food and Drug Administration (FDA) has marketing approval 
requirements for pharmaceutical products procured under the US President’s 
Emergency Plan for AIDS Relief (PEPFAR). These mitigate against the purchasing 
                                                 
33 http://mednet3.who.int/prequal/ Campaign for Access to Essential Medicines, Untangling the web of 
price reduction: a pricing guide for the purchase of ARVs for developing countries, 6th ed., April 2004 
34 Regulation (EC) No 726/2004 (31 March 2004), Article 58, OJ L 136, 30.4.2004, p.1 
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and distribution of generic drugs in developing countries,35 which are often cheaper 
than drugs produced by R&D based companies. 
3.1.3. Developing local manufacturing capacity 
Local production: The PfA calls for increased assistance to developing countries to 
develop high-quality local production of key pharmaceutical products. The EC 
supported a feasibility study in the local production of condoms in several African 
countries, which demonstrated that there is clear potential for local production in 
several main countries. 
So far, progress has been slow. Local production is now one of three priority areas in 
the calls for proposals 2003-2006 for the budget line on Aid for Poverty-Related 
Diseases. This presents the possibility of supporting innovative actions, which could 
then be scaled up, potentially through other instruments such as country budget lines, 
the European Investment Bank and the Centre for Development of Enterprise 
(specified by the Cotonou Agreement). 
                                                 
35 The President’s Emergency Plan for AIDS Relief (PEPFAR) is a US initiative launched by the 
American President, which commits US$15 billion to HIV/AIDS over five years with particular focus 
on 15 countries (12 of those in sub-Saharan Africa). http://www.state.gov/s/gac/ 
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IMPACT 
Key results: 
• A four-fold increase in EC resources allocated specifically to confronting the three 
diseases, at a €259.02 million annual average programmed for 2003-2006 as 
compared to a €59.32 million annual average committed for 1994-2002, 
illustrating the increased commitment to confronting the three diseases. This 
includes a 4-fold increase in funds from the 5th to the 6th FP (RTD) (from €109 
million, 1998-2002, to more than €400 million, 2002-2006) allocated to research 
on HIV/AIDS, malaria and TB. 
• More flexibility in funding, and accelerated disbursement, to confront the three 
diseases. Firstly, responsive use of the intra-ACP budget line to support new 
partnerships and distribute greater resources at country level (this includes EC 
leadership and substantial support for the Global Fund). Secondly, new 
instruments (the budget line on Aid for Poverty-Related Diseases) to support 
innovative actions at global level and faster disbursement to demand-driven 
proposals in countries. 
• EMEA now able to evaluate pharmaceutical products intended exclusively for 
markets outside the EU. These provisions respond to the need to protect public 
health and give scientific assistance to developing countries. 
Key Challenges: 
• To encourage countries most affected by the three diseases to prioritise health, and 
investment in the strengthening of the health system and sustainable long-term 
financing. 
• To monitor health outcomes in countries where the EC provides health and/or 
macroeconomic budget support. Presently, it is difficult to show impact beyond 
resource allocation. 
• To ensure, in the new EC financial perspectives, predictable and sustainable but 
also flexible funding targeting the three diseases, within the context of support for 
strengthened health and other social services. 
• To strengthen the regulatory capacity of countries (possibly through WHO 
support). 
• To accelerate local production of some pharmaceutical products in developing 
countries, including by strengthening local capacity. 
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3.2. Affordability 
Rationale for action: At the time of developing the policy framework,36 prices of 
some key pharmaceutical products for the three diseases were unaffordable for 
households and countries. It would not have been the best use of ODA to support the 
purchasing of such expensive products. To give one example, in 2000 when the EC 
policy framework was adopted, the price of patented ARV was around 
US$10,000/person/year. 
Political pressure and policy decisions: Various factors contributed to the price 
decrease in some key pharmaceutical products, the most important of which are 
discussed below. The EC has played a leading role in most, if not all, of them. Some 
were planned actions under the PfA, for example the promotion globally of tiered 
pricing, and issues relating to intellectual property. Other factors were the result of 
the synergy and interplay of PfA actions, for example the EC’s partnership with civil 
society and developing countries on issues of global advocacy, and the increase in 
demand for ARVs due to Global Fund funded projects in-country. 
Sustained public pressure and advocacy from civil society and international 
organisations, and the eventual responsiveness of the corporate community in 
acknowledging the importance of prices, are key reasons behind the fall in prices of 
pharmaceutical products. 
The most important area of progress in the past few years with regard to the three 
diseases is the dramatic reduction in price of anti-retrovirals (ARVs) to treat 
HIV/AIDS. In September 2000, a major announcement made by Cipla (an Indian 
generic pharmaceutical product manufacturer) at the EC Round Table discussion37 
initiated the price reduction in ARVs to around US$500 per person per year. R&D 
based pharmaceutical companies also committed themselves to large price reductions 
(GlaxoSmithKline at the same Round Table) at around the same time.38 Today, the 
lowest prices for first-line ARV treatment are between $100-$350 per person per 
year.39 
Increasing transparency: The 2003 progress report identified the need for 
improved transparency in prices of pharmaceutical products. It is unsatisfactory to 
                                                 
36 Affordable drugs are also included in the MDGs, Goal 8, Target 17 – “In cooperation with 
pharmaceutical companies, provide access to affordable, essential drugs in developing countries”; in the 
Amsterdam targets for TB – “By 2005, 70% of people with infectious TB will be diagnosed, and 85% 
cured”; and in the Abuja targets for malaria – “Ensure that by 2005 at least 60% of those suffering from 
malaria have prompt access to, and are able to correctly use, affordable and appropriate treatment 
within 24 hours on the onset of symptoms.” 
37 This Round table was hosted by the EC to ensure broad consultation on the Communication (2000). It 
was organised in partnership with WHO, UNAIDS, and 170 stakeholders, including developing 
countries, the European parliament, civil society, and leaders of major pharmaceutical companies. 
Stakeholders reached a wide level of consensus. 
38 In May 2000, five pharmaceutical R&D based companies announced a new partnership (the 
Accelerating Access Initiative), which specified less expensive drug prices for the poorest countries and 
countries where HIV/AIDS prevalence is highest. 
39 WHO, “3 by 5 Progress Report December 2003 through June 2004”, 2004 
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rely on fragmentary data. One success of the past few years has been the gradual but 
slow increase in price transparency, especially from Principal Recipients buying 
pharmaceutical products under Global Fund-supported contracts. Some NGOs also 
show what prices they pay for procuring products, and some manufacturers have 
started to be themselves more transparent about prices. The increasing price 
transparency facilitates the comparison of prices, informs potential buyers and 
ensures that market competition contributes to reducing prices in developing 
countries. Exact details on prices remain hard to obtain; Annex 3 illustrates some 
prices of certain key ARVs, as published on the web-page of the Global Fund. The 
Global Fund has a Price Reporting Mechanism where Grant Recipients have to 
publish the prices they paid for pharmaceutical products purchased under Global 
Fund projects. 
3.2.1. Tiered Pricing 
EC Regulation on trade diversion: The concept of tiered pricing (that buyers in 
developing countries should have access to medicines at considerably lower prices 
than buyers in more well-off countries) is one that the EU has consistently 
emphasised. Pharmaceutical producers in developed countries need security that 
discounted products supplied in large volumes do actually reach the poor countries 
they are meant for and are not diverted back into high price markets. This will enable 
them to enter new markets and support the reduction of communicable diseases. In 
May 2003, the Council therefore adopted a Regulation to avoid trade diversion into 
the European Union of certain key medicines.
40 
The Regulation aims to encourage producers to significantly increase supplies of 
medicines at tiered prices in developing countries, while maintaining higher prices 
for the same products in the EU. Exporters are invited to register their products on a 
tiered price list established by the EC.41 The Regulation responds to the danger of 
diversion of cheap imported medicines from poor countries into high price markets, 
and provides an incentive to reduce prices further. It also ensures that price 
reductions are sustainable for the producer and predictable for the purchaser. To 
some extent, it also enhances transparency. 
Both patented and generic products can be registered, as can donated products. In 
order to be added to the list, medicines have to be made available either with a price 
cut of at least 75% off the average ‘ex factory’ price in OECD countries, or at the 
cost of production plus maximum 15%. The proposed system is simple and 
transparent, with products on the list bearing a logo for identification purposes.42 The 
Regulation makes no differentiation between products sold to public authorities, 
NGOs, and private buyers. In developing countries, medicines frequently consume a 
significant proportion of private household expenditure. Therefore, the price of 
pharmaceutical products in the private market is as important as those sold to public 
authorities and a key determinant of access. 
                                                 
40 Regulation (EC) 953/2003. OJ L 135, 3.6.2003, p.5 
41 http://trade-info.cec.eu.int/cgi-bin/antritradediversion/index.pl 
42 http://europa.eu.int/comm/trade.csc.med.htm 
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As the 2003 progress report identified, the Regulation is the start of a successful 
tiered pricing policy that will contribute to increased affordability. To date, 
GlaxoSmithKline (a leading manufacturer of ARVs which has strongly supported the 
tiered pricing policy from the beginning) has registered 7 HIV/AIDS products under 
the Regulation to be protected against trade diversion.43 Two further applications 
from GlaxoSmithKline are still pending and will be processed before the end of 
2004. The company is also advocating the merits of the EU Regulation to other 
pharmaceutical R&D based companies.44 The first annual report of the activities 
under the Regulation will be published in the autumn of 2004, showing the volumes 
of exports of tiered priced products. In accordance with the Regulation, the EC will 
issue a standard form by which manufacturers and exporters registered under the 
Regulation will report their annual volumes. Under the Regulation, the EC is also 
required to periodically report to the Council on the volumes exported under tiered 
prices. 
EC advocacy of tiered pricing: The EC is encouraging other developed countries to 
introduce a tiered pricing policy. As specified in the PfA, the EC is currently 
engaged in an informal dialogue with Japan on the issue of access to medicines. The 
Japanese government informed the EC that Japan did not produce or export 
treatments for HIV/AIDS, tuberculosis or malaria and that, therefore, a tiered pricing 
policy was not necessary. However, the Japanese government responded positively 
to the possibility of extending the current dialogue to the broader issue of increasing 
access to medicines for developing countries. No progress with other major countries 
has been achieved. 
The EC policy framework (2000) argued strongly that there is an inverse relationship 
between the price of pharmaceutical products sold in developing countries and the 
number of people treated (i.e. volumes sold). This relationship appears to have been 
borne out in practice. The increase in treatment uptake as supported by country 
strategies, the Global Fund, NGOs such as Médecins Sans Frontières (MSF), the 
Global Alliance for Vaccines and Immunization (GAVI)45 and calls such as the 3 by 
5 Initiative are starting to increase the number of people being treated.46 This has 
only been possible through price reductions, which made increased treatment a 
realistic possibility. 
                                                 
43 Trizivir 750mg, Epivir 150 mg, Retrovir 100 mg, Retrovir 250 mg, Retrovir 300mg, Combivir 
300/150mg, Epivir Oral Solution 10mg/ml 240ml 
44 From DFID ‘Increasing access to essential medicines in the developing world: UK Government policy 
and plans’, June 2004 
45 The Global Alliance for Vaccines and Immunization (GAVI) is a public-private partnership launched in 
2000 which through the Vaccine Fund provides financial resources to countries to purchase vaccines 
and other supplies and to support the operational costs of immunisation. 
http://www.vaccinealliance.org/home/index.php 
46 Launched on World Aids Day 2003 by the WHO, the 3 by 5 Initiative is a call for reaching three 
million people living with HIV/AIDS (including 2 million in Africa) by 2005 with antiretroviral 
treatment. http://www.who.int/3by5/en/ 
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3.2.2. Tariffs and taxes 
Another activity specified in the PfA was to work towards eliminating the hurdles of 
tariffs, taxes and importation, distribution, and local registration fees in importing 
countries. This was intended to further eliminate hurdles to access to pharmaceutical 
products. An EC study on duties and taxes on pharmaceutical products in 57 
developing countries47 showed that there is still scope for lowering tariffs and taxes 
in some countries. The range of duties and taxes currently varies from 55% on most 
pharmaceutical products in India to 0% in countries such as Cuba, Gabon, Indonesia, 
Iran, Malaysia, Nicaragua and Uganda. This issue is being addressed on a bilateral 
basis through EC trade and policy dialogue. 
3.2.3. Use of flexibilities within the Agreement on Trade-Related Aspects of Intellectual 
Property Rights 
The World Trade Organisation Agreement on Trade-Related Aspects of Intellectual 
Property Rights (TRIPs) defines minimum standards for intellectual property 
protection in WTO Member States. This is important for the development of 
research-based pharmaceutical products to allow a return on investment, which is 
reflected in the price of patented pharmaceutical products. From the outset, the EU 
has been at the forefront of efforts to ensure access to affordable pharmaceutical 
products for developing countries. In the WTO, the EC has played a lead role by 
acting as a bridge-builder to bring together the almost irreconcilable positions of the 
opposing sides. These efforts were most apparent in the results of the negotiations in 
Doha, where the WTO agreed on a groundbreaking Ministerial Declaration on the 
TRIPs Agreement and Public Health (November 2001), which reaffirmed existing 
flexibilities within TRIPs, including that the Agreement should not prevent countries 
from taking measures to improve public health and promote access to medicines. The 
Declaration affirms that these flexibilities comprise the use of compulsory licensing 
in order to serve developing countries’ markets. The Declaration also defers the 
obligation for Least Developed Countries to enforce patents on pharmaceutical 
products until 2016. 
The Doha Declaration left one issue unresolved: countries with no manufacturing 
capacity for pharmaceutical products, which include those in greatest need of 
affordable drugs, would not benefit from the use of compulsory licences. To serve 
the needs of their markets, those countries need to import medicines. However, 
Article 31(f) of the TRIPs Agreement stipulates that compulsory licences must be 
“predominantly for the supply of the domestic market of the Member authorising 
such use”. Therefore, the granting of compulsory licences for the sole purpose of 
exportation was not allowed. The EC was strongly supportive of finding a quick 
solution. In this context, in April 2003, the EC organised a “Round Table on Access 
to Medicines”.48 One of the main objectives of the Round Table was to recommend 
how the G8 Summit in Evian in June 2003 could progress on this critical issue. Over 
90 external participants attended, representing international organisations, 
                                                 
47 http://europa.eu.int/comm/trade/issues/global/medecine/ttr.htm 
48 http://europa.eu.int/comm/trade/csc.med.htm 
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governments of developed and developing countries, R&D based industry, generic 
industry, pharmaceutical associations and NGOs. 
In August 2003, the WTO General Council adopted the ‘Decision on the 
Implementation of Paragraph 6 of the Declaration on the TRIPs Agreement and 
Public Health’. Under certain conditions, WTO members with no or limited 
manufacturing capacity may now purchase drugs, in order to address a public health 
problem within their territory, produced under a compulsory licence in a WTO 
member with manufacturing capacity. 
National patent laws in exporting countries need amendment to provide for this. 
Discussion on a formal amendment to the text of the TRIPs Agreement continues in 
the WTO TRIPs Council, with the aim of reaching agreement by June 2005. While 
this amendment remains in preparation, those developing countries wishing to use 
the mechanism to import essential medicines today will not face litigation (WTO 
dispute Settlement Mechanism) as a result. The EC is finalising a draft Regulation to 
implement this decision to be directly applicable in the EU. It contains the necessary 
safeguards and other conditions that are necessary when an EU Member State 
becomes an exporter under the new system. 
The EC/EU attaches great importance to ensuring that the Doha Declaration is not 
undermined either in the formal amendment of the TRIPs Agreement, through 
bilateral negotiations, or through national legislation. Recently, some negotiating 
partners (particularly the US) have been criticised for seeking regional and bilateral 
free trade agreements (FTAs) in which developing countries are asked to refrain 
from using the flexibilities as provided by the Doha Declaration by more stringent 
provisions in the FTAs.49 Criticisms have also been levelled for delaying 
amendments to the TRIPs Agreement pursuant to the 30 August 2003 Decision. The 
EC and EU Member States have voiced criticism of the US for such actions. 
Another way in which the EC has been supporting adherence to the commitments 
made in Doha 2001 is through the World Intellectual Property Organisation (WIPO). 
At the WIPO General Assembly in 2003, the EC and EU Member States made a 
statement that the adoption of the Doha Declaration and the decision on paragraph 6 
should be reflected in WIPO’s technical assistance. In addition, the Commission has 
engaged in a dialogue with WHO on health and trade matters, resulting in more 
information exchange and reinforced cooperation in public health matters. 
Beyond affordability to access: The reduction in the price of ARVs and other 
pharmaceutical products is necessary to increase access, but is not sufficient in itself. 
Lower prices can be a catalyst for change, and stimulate progress in other areas that 
are essential to promote access. These include effective procurement, regulatory 
control, transport and storage facilities and an efficiently functioning health 
infrastructure with referral mechanisms in place, essential logistics supply 
                                                 
49 Undermining access to medicines: Comparison of five US FTAs – A technical note (OXFAM, June 
2004). http://www.oxfam.org.uk/what_we_do/issues/health/undermining_access_ftas.htm 
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mechanisms and appropriately trained, employed, remunerated and effectively 
managed health staff to deliver the medicines and supervise treatment. 
Most of the people suffering from HIV/AIDS, malaria and TB live in the poorest 
countries, and belong to the poorest sectors of society. Even where there are existing 
and effective technologies and interventions, many people do not have access to 
them. Further reduction in prices would increase the number of countries and the 
pool of people able to afford them, especially those living in least developed 
countries where US$150 per person per year – the cost of a first-line ARV – is still 
far beyond what national health budgets or individual incomes can support. 
In 2000, there were still more than 2,700,000,000 people living on less then 
US$2/day.50 As of June 2004, 440,000 people were estimated to have received ARVs 
out of a total estimated number of six million people in immediate need of treatment 
in developing countries (only 8%). This is an increase of 40,000 from the total 
number of people on treatment in 2003.51 According to the 3 by 5 Initiative Progress 
Report (December 2003 through June 2004), access to ARV medicines in 2002 
increased by 50% globally, and by two-thirds in sub-Saharan Africa. This excludes 
Brazil, which still accounts for about 33% of all people on ARV therapy in 
developing countries.52 
AFFORDABILITY 
Key results: 
• A reduction by up to 98% in the price of some key pharmaceutical products in 
developing countries. 
• Global acceptance of tiered pricing as a sound principle, an established definition 
of what constitutes a maximum threshold for a tiered price, and anti-trade 
diversion measures put in place for registered products. 
• Agreement reached on all aspects of the Doha Declaration on TRIPs and Public 
Health, including Paragraph 6, which allows countries with insufficient 
manufacturing capacity to import less expensive pharmaceutical products to 
address a public health problem. 
Key challenges: 
• To accelerate price reductions (i.e. make tiered pricing the norm) in developing 
countries, and to broaden the range of more affordable pharmaceutical products. 
• To reduce or eliminte import tariffs on essential pharmaceutical products to ensure 
lowest possible consumer prices in developing countries. 
                                                 
50 Global Economic Prospects 2004, World Bank www.worldbank.org/prospects/gep2004/chapter1.pdf 
51 WHO, “Treating 3 Million by 2005: Making it Happen. The WHO Strategy”, 2003 
52 3 by 5 Progress Report – December 2003 through June 2004. 
http://www.who.int/3by5/publications/progressreport/en/ 
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• To continue to improve transparency of prices of pharmaceutical products and 
price reductions, through the Regulation on trade diversion and through the 
Global Fund. Public advocacy and support for greater price transparency is an 
underplayed card in the affordability arena. 
• To support developing countries’ capacity to use flexibilities under the Doha 
Declaration, and to ensure that the Doha Declaration is not eroded (through 
bilateral agreements). 
• To go beyond affordability to promote access, primarily through developing 
functioning health infrastructure with appropriately trained, employed, 
remunerated and managed staff. 
3.3. Research and development of new tools 
Rationale for action: The PfA calls for continued and increased support for basic 
and strategic research on new tools for the three poverty diseases, with greater 
coordination at European and international level. The PfA calls for the creation of a 
European and Developing Countries Clinical Trials Partnership (EDCTP) to increase 
the number, efficiency and coherence of clinical trials carried out in developing 
countries in Africa with a high disease burden. It also calls for incentives to harness 
the capacity of private industry to invest in and develop new tools targeting the three 
diseases. 
The EU’s support remains strong. In June 2004, at a conference bringing together a 
multitude of private and public partners held in Dublin and co-hosted by Ireland and 
the Netherlands, the EU endorsed the Global HIV/AIDS Vaccine Enterprise, and 
agreed on priority actions to improve and speed up the development of new 
preventive technologies such as HIV vaccines and microbicides. 
The 6th FP (RTD) for 2002-2006 was adopted by the European Parliament and the 
Council in June 2002.53 Compared to the 5th FP (RTD) for 1998-2002, the indicative 
budget for poverty-related diseases under the 6th FP (RTD) is substantially higher, 
with more than €400 million being allocated to basic, pre-clinical and clinical 
research in new interventions for HIV/AIDS, malaria and TB (a 4-fold increase from 
€109 million). Substantial efforts have since been made to gather a critical mass of 
private and public partners, from developed and developing countries in a limited 
number of relatively large project consortia, typically handling budgets in the range 
of €5-20 million. The Quality of Life approaches54 have been consolidated in the 6th 
FP (RTD), where research in poverty-related diseases has become a specific budget 
item under the first priority thematic area (life sciences, genomics and biotechnology 
                                                 
53 Decision No 1513/2002/EC. OJ L 232, 29.8.2002, p.1 
54 The 5th Research Framework Programme ran between 1998 and 2002, and the EC provided substantial 
funding to a broad range of research activities relating to the three diseases, notably via specific calls for 
proposals. A total of 77 projects were supported with more than €109 million under two separate 
programmes – Quality of Life and International Cooperation. The approach in the Quality of Life 
programme focused on bio-medically-oriented and clear deliverables, while the International 
Cooperation programme used a networking approach to build up numerous North-South partnerships. 
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for health). The International Scientific Cooperation programme continues to support 
North-South collaborative research projects on health systems and policies, other 
neglected diseases, child survival, and reproductive health. 
Currently, a number of highly significant research projects are under way and 
delivering results, funded by the 5th FP (RTD). These include a multicentre trial of 
shortening TB treatment to four instead of six months, a series of early clinigal tests 
for TB vaccination, and various projects dealing with new malaria drugs such as 
phosphidomycin. Another significant action is the support to a pioneering effort of 
HIV/AIDS vaccine research in China, based on the locally predominant C-strain of 
the HIV virus. 
3.3.1. Strengthening of research in poverty-related diseases 
The EC has made an important contribution to confronting HIV/AIDS, malaria and 
TB by pooling knowledge, experiences, human and financial resources from the 
different stakeholders in the research and development process. The 6th FP (RTD) 
has given increased opportunities to organising and funding large-scale research 
projects, with a high and lasting potential impact. The EC is now supporting a much 
wider range of research activities, expanding from early discovery to clinical trials 
and comprising an extensive pipeline of promising development projects. Since the 
launch of the PfA, European research in poverty-related diseases has become ever 
more visible, influential and effective on the global research agenda and in its 
priorities. Alliances have been created with foundations and industry, and closer 
interaction with national and international organisations has been implemented. 
Support for large research consortia: The significant funding allows for large 
consortia with diversity and critical mass to undertake complete product/intervention 
development projects. Development of promising drug and vaccine candidates from 
discovery phases to early human testing is undertaken by multidisciplinary research 
consortia that are organised as Integrated Projects (IPs) or Networks-of-Excellence 
(NoEs). So far, support has been given to 6 projects with a total budget of €160 
million and an EU contribution of €73 million. The 6 projects cover malaria biology 
(EU contribution of €15.5 million), TB and HIV vaccine development (EU 
contributions of, respectively, €16.8 million, €15.5 million and €10 million), as well 
as microbicides (EU contributions of €3.8 million and €11.7 million). During the 
next two years of the 6th FP (RTD), funding will be provided to drug development 
projects in malaria and TB, while other projects should focus on further development 
of HIV/AIDS and malaria vaccine candidates. 
Support to several small-scale, high-risk and innovative projects: Research in 
poverty-related diseases is a long-term and complex activity, and innovation is 
needed in order to maintain a wide initial scope. The EC supports several small-
scale, high-risk and innovative projects, all in the early discovery phase. Based on 
project results, the EC will be able to select interventions that may enter the first 
stages of the formal development pipeline. Individual projects have a duration of 2 
years, and budgets of €1-2 million. Approximately 20 projects involving 102 
research groups representing all three diseases have so far been selected for support. 
More projects will be added during the next 2 years of the 6th FP (RTD). 
 EN 31   EN 
Utilising the innovative potential of SMEs: It is expected that opportunities offered 
to the Small and Medium-sized Enterprise (SME) sector, by means of specific calls 
for proposals and appropriate use of instruments of the 6th FP, could enhance their 
participation in this field. 
Partnerships: The overarching methodology of poverty-related disease research in 
the 6th FP (RTD) is to consolidate genuine partnerships between European scientists, 
research teams from disease-endemic countries and industry. The projects described 
above involve a significant number of industry partners, thereby generating a 
synergy between academic and industrial research. Research teams from developing 
countries have been particularly encouraged to join the projects, and this has resulted 
in the active participation of 12 renowned African institutions. 
Despite this progress, many research efforts are not sufficiently coordinated on the 
ground between the different stakeholders in the most affected endemic countries. 
There is little investment into the development of scientific learning, further training 
of health practitioners or in positive local synergies between research and routine 
health care programmes. There are also other research areas, such as social analysis, 
the analysis of new epidemiological trends and the development of methods on how 
to measure impact of interventions, which have not been appropriately addressed so 
far. These are of particular importance for vector-borne diseases like malaria. 
Training fellowships: Significant efforts have been made to provide for increased 
training activities in the area of research on poverty-related diseases, in particular 
through the larger IPs and NoEs of the 6th FP (RTD). Very encouraging examples 
can be found in the malaria research NoE (BIOMALPAR), where the European 
Molecular Biology Laboratory makes its expertise available. 
3.3.2. European and Developing Countries Clinical Trials Partnership 
The European and Developing Countries Clinical Trials Partnership (EDCTP) 
initiative was established in 2001 in response to one of the three areas for action in 
the PfA – to increase research and development of specific global public goods to 
confront the three diseases in developing countries. The aim was to unite and 
coordinate Europe’s clinical trial activities specifically targeting interventions for use 
in developing countries. The single largest budget allocation of the 6th FP (RTD) 
(€200 million) goes to the EDCTP. The EDCTP’s mandate focuses on supporting 
phase II and phase III clinical trials for new interventions confronting the three 
diseases and on research-oriented capacity building, particularly in sub-Saharan 
Africa. 
The EDCTP programme was adopted by the European Parliament and the Council in 
June 2003.55 The programme started operations in autumn 2003 after a legal entity, 
the European Economic Interest Grouping (EEIG), was formed by the participating 
states (14 EU Member States and Norway), external from the Commission and 
headquartered in The Hague. The EDCTP now operates its own implementation 
                                                 
55 Decision No 1209/2003/EC of 16 June 2003. OJ L 169, 9.7.2003, p.1 
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structures, calls for proposals and appropriate selection and evaluation procedures. 
An African office of the EDCTP was opened in Cape Town in July 2004. 
A first call for proposals for clinical trial projects and senior fellowships for African 
scientists and clinicians has been issued in early 2004. A total of nine projects on 
improved treatment for HIV/AIDS, malaria and TB and six fellowships have been 
selected for funding through an independent scientific review procedure. A second 
call for proposals, targeting upgrading of research capacity of African vaccine trials 
sites, is currently underway. 
African ownership and representation in the EDCTP is established at different 
levels: at the Scientific/Advisory level, the composition of the Partnership Board 
(North-South is 50/50); at the Structural/Organisational level with the establishment 
of the African EDCTP Secretariat in Cape Town, the functioning of the Developing 
Countries Coordinating Committee as an EDCTP external entity for the 
representation of the African scientific community to the EDCTP programme; at the 
Advocacy/External level with the role of Dr Mocumbi, the High Representative of 
the EDCTP; and finally, at the Project level, where in the nine selected projects from 
the first call, 31 partners are African institutions representing 16 sub-Saharan African 
countries. 
Through the use of Article 169 of the Treaty, the EC is contributing €200 million to 
the EDCTP (for the whole time period 2002-2006). Another €200 million comes 
from the 15 participating European countries, the Netherlands having already 
committed significant funds. Further input is expected from industry, foundations 
and other private sector sponsors. 
The EDCTP is a pilot programme and a unique initiative in research at the European 
and global level. Key components include: 
• It contributes to the first implementation of Article 169 of the EC Treaty, which 
allows the participation of the European Community in EU Member States’ 
national research and development programmes. 
• It is the largest programme on clinical trials in Africa. 
• It has an entrepreneurial legal entity, more flexible to take up the challenges. 
• It consolidates a genuine partnership between the South and the North on a long-
term sustainable basis. 
• It focuses on the needs of developing countries, which are setting the priorities 
and are establishing strategies in close partnership with European countries. 
The EDCTP is thus a concrete example of the functioning of the European Research 
Area and it is fully integrated within the activities of the 6th FP (RTD) (2002-2006). 
3.3.3. Capacity building for research and development in developing countries 
A significant proportion of the EDCTP budget contributes towards the enhancement 
of capacity for research and development in developing countries with a high disease 
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burden. Capacity building is an essential component of the EDCTP. Nevertheless, 
the needs largely outweigh the resources of the programme. Capacity building is 
needed in terms of personnel training, support for new and existing health 
infrastructures as well as setting up the adequate organisational, technical/scientific 
and institutional frameworks. 
While the 6th FP (RTD) funds mobilised under Article 169 can contribute to the 
implementation of EDCTP programmes’ clinical trials and research-related capacity 
building activities, additional funds from both private and public sources are needed 
to allow the EDCTP programme to achieve its full impact potential. Such funds are 
required, for example for high-quality production of medicines and vaccines, for 
implementation of new interventions, and for strengthening health systems and care 
facilities in Africa. 
3.3.4. Indirect incentives to increase R&D investments of the private sector in specific 
Global Public Goods 
Incentives: The PfA identified the crucial role of private investors in developing 
tools to confront the three diseases. Since pharmaceutical R&D is complex, risky and 
expensive, developing new drugs or vaccines for low-income countries is unlikely to 
occur without significant public incentives. The 2003 progress report recommended 
that further work be done to increase incentives to the private sector to invest in new 
specific global public goods targeting these diseases. The EC has since reinforced the 
dialogue with the R&D based industry, European industry organisations, health 
economists and other stakeholders to identify those public incentives most likely to 
boost private investments in the development of essential pharmaceutical products, 
including HIV vaccines and microbicides. The menu of incentives being discussed 
includes the extension of patent rights and/or market exclusivity, including through 
the relationship which might be established between different products, venture 
capital, low cost loans, tax credits and guaranteed markets. Through these 
consultations, the EC has identified the need for further studies on: 
(1) Costs and benefits of developing an AIDS vaccine, a microbicide and a malaria 
vaccine 
(2) Impact of introducing different incentives on private research intensity, both in 
the large pharmaceutical and small and medium-sized enterprise sector 
(3) Potential long-term impact on global public health of introducing different 
incentives 
(4) Financial requirements, including an assessment of costs of different incentives 
for public authorities and individual citizens 
(5) Identification of various EC instruments which could be used to provide 
incentives, including potential new EU regulations and related legal issues. 
Community preparedness for potential vaccines and microbicides: It is 
imperative to test new tools in developing countries, where they are most needed. 
The EC is taking a parallel approach and preparing developing countries for the 
possibility of introducing AIDS vaccines and microbicides. This is in anticipation of 
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the technological breakthroughs, and will eventually ensure a smooth and fast 
distribution implementation mechanism. The EC is working on community 
preparedness directly with communities in sub-Saharan Africa, and with 
international partners such as IAVI, IPM,56 and the South African AIDS Vaccine 
Initiative. EC work includes the funding of programmes on ethical criteria and 
regulatory aspects. The EC also held discussions on affordability clauses (with 
IAVI), regulatory aspects (EMEA), and production and distribution capacities. The 
discussion has not yet started on what price would be affordable and morally 
acceptable for AIDS vaccines in developing countries. A potential precedent for 
tiered pricing has already been set through the Regulation. The EC also funded a 
joint economic research programme with the World Bank to assess the potential 
demand and impact of an AIDS vaccine (see Annex 2 for information on financial 
support by EU Member States to IAVI and IPM). 
                                                 
56 Various EU Member States are also supporting these organisations, see Annex 2. 
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RESEARCH AND DEVELOPMENT 
Key results: 
• A 4-fold increase in funds from the 5th to the 6th FP (RTD) (from €109 million, 
1998-2002, to more than €400 million, 2002-2006) targeting the three diseases. 
• Support for large research consortia, with strong partnerships developed between 
European scientists, renowned African research institutions, and industry partners. 
• Support for small-scale, high-risk and innovative projects in the early discovery 
phase and incentives for participation by SMEs. 
• The establishment of the European and Developing Countries Clinical Trials 
Partnership, which focuses on supporting phase II and phase III clinical trials for 
new interventions confronting the three diseases and on research-oriented capacity 
building, especially in sub-Saharan Africa. In only one year, all decision-making, 
organisational and managerial components of the EDCTP programme are 
operational. The participation in and ownership of African countries and 
researchers in the EDCTP programme is a significant achievement. 
• The preparation of developing countries for the possibility of introducing AIDS 
vaccines and microbicides. Early results show that people are willing and able to 
pay, use and test these new tools. 
Key challenges: 
• To sustain EU (EC and EU Member States) funding to promote further 
development of key tools to confront the three diseases, including an AIDS 
vaccine, microbicides and TB diagnostics. 
• To prioritise close coordination and increased coherence of clinical testing 
(recommended to be done in parallel), in order to accelerate the release of new 
tools. Also, to ensure better cooperation between different stakeholders on the 
ground. 
• To ensure sustainability and increase in EDCTP support, with an appropriate mix 
of EC, EU Member State and private sector funding. 
• To establish incentives for private industry to develop new targeted products, 
ensuring cost effectiveness of such interventions. 
3.4. Participation in Global Partnerships: Policy and Political Dialogue 
The EC has developed strong partnerships with various key players, including policy 
dialogue with NGOs and pharmaceutical companies and enhanced cooperation with 
UNAIDS and WHO, despite the lack of formal channels for such dialogue and 
partnerships. EC cooperation with UN agencies now includes funding (as a new 
component) which, in the case of WHO, is part of a formal, strategic partnership with 
the EC which defines areas for further cooperation. 
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Partnership with developing countries: The EC has worked in partnership with 
developing countries to confront HIV/AIDS, malaria and TB at global, regional and 
country level. As described above, the EC has supported programmes that directly 
address the three diseases at country level, both through country strategies and the 
Global Fund. In many of these countries, EC delegations have been active in the 
Country Coordination Mechanisms (CCMs) of the Global Fund. EC contributions to 
confronting the three diseases in other countries have come through health as a focal 
sector, and/or through macroeconomic budget support. In the area of research and 
development, the EC has formed strong partnerships with research institutions of 
developing countries, primarily through the EDCTP as described above. 
Partnership with civil society: The EC has actively called upon the participation of 
civil society in policy consultation and formulation. This has resulted in a new 
partnership and dialogue with international and national non-governmental 
organisations (NGOs), including those representing women, people living with the 
diseases, and those representing sexual and reproductive health and rights. NGOs 
have increasingly become more than implementers of programmes using EC funds, 
and are important partners in policy dialogue. 
Partnership with the private sector: A growing body of evidence suggests that if a 
company is investing in a developing country or in a middle-income country such as 
Brazil, China, Russia or South Africa, HIV/AIDS is also their business. For many 
businesses, investment in programmes that prevent infection and provide care and 
treatment for employees with HIV/AIDS makes business sense. Companies are now 
increasingly offering services for voluntary testing and treatment of employees and 
families, condom provision and education. The EC has been working with investors 
in Africa to encourage the provision of preventive and care programmes either 
directly or indirectly. Investing in such programmes improves the welfare of their 
employees, and makes them more productive. Such programmes also generate 
goodwill and raise the company’s standing in society. 
The EC has worked in close partnership with the private sector, including the R&D 
based industry, private enterprises (e.g. Private Investors for Africa) and other key 
stakeholders in the dialogue, development and implementation of national and global 
strategies. The active policy dialogue and partnership with the R&D based industry is 
now resulting in an improved understanding of development objectives and business 
incentives. 
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Leadership in countries: Certain developing countries have demonstrated strong 
leadership and successful strategies that have stopped or reversed infection rates for 
HIV, malaria and TB over the past few years57. Peru has attained effective TB 
control nationwide through integrating TB control within the health system 
throughout the country, and maintaining high quality service, monitoring, and 
management of the system. Senegal saw early mobilisation of government and civil 
society. There was also open government support for reproductive health, including 
sexually transmitted disease and HIV prevention, and HIV/AIDS treatment through 
ARVs. These measures have kept the disease prevalence low. In Thailand, strong 
prevention efforts promoting the use of condoms, production of generic 
pharmaceutical products, and testing and treatment have contributed to decreasing 
annual infection rates in certain groups by a factor of five over the last decade. 
Thailand’s treatment and care approaches have also been supported by the 
distribution of generic and locally produced medicines. In Uganda, national 
prevalence of HIV/AIDS dropped from 12% in the early 1990s to 4.1% in 2003 (in 
the capital Kampala, this trend was even more pronounced, with a prevalence of 
around 8% in 2002 as compared to 29% ten years ago). This reduction was mostly 
due to education campaigns to mobilise various leaders, and condom promotion. 
However, this momentum must be continued – a recent survey suggests that young 
people in Uganda may have less AIDS knowledge than their counterparts in the 
1990s58. In Vietnam, child mortality rates due to malaria have declined over the last 
decade, primarily because of the use of insecticide-treated bednets and community-
based diagnosis and treatment.  
The countries mentioned above have varying reasons for their success. Most notable 
is that of leadership, with political commitment behind strong policies, the effective 
mobilisation of resources to confront these three diseases, and social services and 
systems that deliver. 
Global health partnerships: The 2003 progress report already noted success at 
scaling up global partnerships, reaching important international consensus on the 
interventions that will make the greatest difference.59 This is most significantly 
illustrated by the establishment of the Global Fund in 2002 after an active transition 
period with the support of the EC and Belgium. Significant new partnerships have 
been made over the past few years with multilateral organisations such as UNAIDS 
and WHO, primarily on issues of pharmaceutical policy and affordable 
pharmaceutical products. For example, the EC is funding WHO to strengthen the 
capacity of countries at national level to monitor health data. 
                                                 
57 WHO, UNICEF, UNAIDS, World Bank, UNESCO, UNFPA, Health a key to prosperity: Success 
Stories in Developing Countries, 2000 
58 UNAIDS Fact Sheet (6/7/2004), from: 
http://www.unaids.org/EN/other/functionalities/Search.asp?StartRow180 
59 This builds on previous agreement on specific targets for malaria at the African Summit on Roll Back 
Malaria in Abuja April 2000; for TB through the WHO Assembly of May 2000; and for HIV/AIDS at 
the UN General Assembly Special Session on HIV/AIDS in June 2001. 
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EC/EU Leadership: The EC has played an active role in terms of advocacy, 
coordinating positions, mobilising resources, and defending and representing strong 
and honest dialogue on the full Cairo agenda among the EU Member States. The EC 
has also regularly held meetings with experts on Health, AIDS and Population from 
the EU Member States to discuss and coordinate policy. EC leadership has been 
exercised as a basis for more coordinated and harmonised cooperation with other 
donors in developing countries and a stronger European voice in international fora – 
including in the WTO, and in the G8. For example, the EC is a key player in the 
policy debate on tiered pricing with the G8 and with the R&D based industry. 
Partnership with EU Member States: There was good cooperation and agreement 
on the PfA between EU Member States in 2001,60 as is indicated by the passing of 
various related Council resolutions (refer to Annex 1). However, the past few years 
have seen dispersion of strategies by Member States. This is indicative of a wider 
trend occurring globally – for example, as evidenced by the different initiatives to 
confront the three diseases. In April 2004, UNAIDS proposed a set of principles – 
the 3 Ones61 to promote harmonisation at country level on HIV/AIDS. These 
principles are: one agreed HIV/AIDS action framework that provides the basis for 
coordinating the work of all partners; one national AIDS coordinating authority with 
a broad-based multi-sectoral mandate; and one agreed monitoring and evaluation 
system at country level. 
                                                 
60 Figures on contributions by Member States to the Global Fund, IAVI and IPM are provided in Annex 2. 
61 The Three Ones, launched in 2004, is an initiative aimed at harmonising donor efforts at country level 
based on three principles: One agreed HIV/AIDS Action Framework that provides the basis for 
coordinating the work of all partners; One National AIDS Coordinating Authority, with a broad-based 
multi-sectoral mandate; and One agreed country-level Monitoring and Evaluation System. 
http://www.unaids.org/en/about+unaids/what+is+unaids/unaids+at+country+level/the+three+ones.asp 
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PARTICIPATION IN GLOBAL PARTNERSHIPS: POLICY AND 
POLITICAL DIALOGUE 
Key results: 
• Strong partnership with developing countries through the Global Fund, through 
CSP and PRSP processes, and through various research activities. 
• Close partnership with a broad range of civil society, who have increasingly 
become important partners in policy dialogue. 
• Sustained and positive dialogue with the private sector, including the R&D based 
industry and private enterprise, regarding corporate social responsibility, 
particularly on HIV/AIDS. 
• Strong EC support for global partnerships in health, including with UN 
organisations and international consortia. 
• Active EC role in terms of advocacy, coordinating positions and mobilising 
resources among the EU Member States. This includes a strong European voice in 
international fora on key issues, including on TRIPs and the Cairo Agenda 
(ICPD). 
Key challenges: 
• How to strengthen further and intensify the dialogue between key partners at 
county level. 
• How to increase the efforts of the private sector, including the promotion of 
private investment and contributions to multilateral initiatives and mechanisms 
(such as the EDCTP and the Global Fund). 
• How to minimise the negative impact of numerous and sometimes divergent 
initiatives through enhanced harmonisation and coordination with EU Member 
States and through global initiatives such as the 3 Ones. 
3.5. Institutional coordination and cooperation 
The policy framework and the PfA required strong coordination, cooperation and 
efforts across different policy areas. No specific EC institutional set-up was created 
to perform the tasks of coordinating, monitoring and reporting on the PfA. Despite 
this, the EC has managed to focus and increase attention through coherent policies, 
resources and efforts in a remarkably short period of time. The EC institutional set-
up has not facilitated the task at hand, and the lack of clear and shared information 
bases has made it very difficult to track results. 
The EC financial instruments are set up in a way which renders supporting global 
instruments difficult. Despite this, the EC has provided significant financial support 
and political commitment to global instruments. 
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The policy framework and the PfA required strong cooperation with a variety of 
stakeholders, outside of historical precedent. The PfA announced the creation of a 
Stakeholder Forum to institutionalise the regular consultation process with 
developing countries, civil society and the private sector. However, this never 
materialised. The EC still retains a great deal of good will with most of the partners 
in providing input and participating in a dialogue. 
4. THE EVOLVING EPIDEMIOLOGY, GEOGRAPHY AND DEMOGRAPHY OF HIV/AIDS, 
MALARIA AND TB 
In total, the three diseases constitute what is generally acknowledged as a global 
emergency – the death of more than 6 million people every year, most of them in 
sub-Saharan Africa. HIV/AIDS is rapidly becoming the worst infectious disease 
catastrophe in recorded history, surpassing in absolute numbers the bubonic plague 
of the fourteenth century and the influenza epidemic of 1917, each of which killed 
around 20 million people.  
Diseases still increasing, and with new forms: Despite increased efforts and 
resources in recent years, the number of people affected, infected and dying from 
HIV/AIDS, malaria and TB continues to rise. In 2003, almost 3 million people died 
of HIV/AIDS, and there were about 5 million new HIV infections.62 It is estimated 
that 38 million people (range between 35-42 million) throughout the world were 
living with HIV/AIDS at the end of 2003.63 By the end of the decade, the number of 
people infected will have grown by another 45 million. Tuberculosis (TB) kills about 
2 million people every year.64 TB is also a major cause of death amongst people 
infected with HIV, and each of the two diseases amplifies the effects of the other. 
Malaria kills more than one million people every year, including an African child 
every 30 seconds.65 
The diseases are also taking on new forms, including multi-drug resistant versions of 
TB, which are especially emerging in Eastern Europe due to poor use of therapy. The 
global picture with regard to malaria shows little sign of improvement, with sub-
Saharan Africa remaining the worst affected region. Climate change, the lack of 
effective vector control, the increase of displaced persons and the rapid extension and 
increase of resistant strains have led to an overall increase in the burden of malaria. 
Geographic spread: Sub-Saharan Africa carries the greatest burden of HIV/AIDS 
and TB; it is home to two-thirds of HIV-infected people globally, although it consists 
of only 11% of the world’s population. An estimated 25 million infected with 
HIV/AIDS live in sub-Saharan Africa. In 2003, approximately 3 million people in 
                                                 
62 Robert Steinbrook, ‘The AIDS Epidemic in 2004’, New England Journal of Medicine, 351;2, 8 July 
2004 
63 UNAIDS “A global view of HIV infection”, www.unaids.org 
64 WHO “Basic Facts on TB”, from www.stoptb.org 
65 WHO “What is Malaria”, from www.rbm.who.int 
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the region became infected, while 2.2 million died of AIDS.66 Women made up 
56.7% of adults infected with HIV by the end of 2003.67 
The populations of China, India and Russia make up half of the world’s total 
population; in all three countries, the HIV/AIDS epidemic is spreading. In China, 10 
million people may be infected with HIV/AIDS by 2010 unless effective measures 
are taken to prevent it; India has the largest number of people living with HIV/AIDS 
outside of South Africa (about 4.6 million in 2002); and in Russia, the number of 
new cases registered doubled between 1987 and 2000 (with 56,630 new cases 
registered in 2000).68 The virus is also spreading rapidly to parts of Eastern Europe 
(including new EU neighbouring countries such as Ukraine).69 
Poverty reduction remains the main framework: HIV/AIDS, malaria and TB 
persist in undermining global efforts to reduce poverty. The three diseases are both a 
consequence of, and a cause of, poverty.70 The most disadvantaged and vulnerable in 
society – e.g. people with disabilities, ethnic minorities, refugees and migrants – are 
the least likely to have access to prevention, treatment and care. They are also 
exposed to more social risk factors, which increase their risks of HIV/AIDS, malaria 
and TB infection, for example overcrowding, malnutrition and poor hygiene. All 
people have the right to realise the highest attainable standard of health (regarding all 
aspects of care, water, food, sanitation, information and education). Poverty is more 
than a lack of income – it is also a condition of powerlessness and vulnerability. For 
poverty reduction to occur, the rights of poor people have to be realised. 
HIV/AIDS also has significant repercussions on economies, reducing economic 
productivity and growth by decimating the workforce. A recent World Bank study 
illustrated how long-term effects of HIV/AIDS could result in economic collapse of 
the worst affected countries.71 Another study illustrates how malaria has hindered 
economic growth in Africa, so much so that the GDP of African countries is 
currently 32% lower than it might have been had malaria been controlled two 
decades ago.72 The diseases also add to the vicious cycle of poverty by inhibiting the 
investment climate of the country, as businesses are less likely to invest in countries 
where the population has a low productivity rate and low purchasing power. 
Morbidity from TB and malaria also negatively impact the economies of societies by 
increasing the burden of disease carried by the working age population. 
                                                 
66 UNAIDS, Report on the global AIDS epidemic, July 2004 
67 IPPF, ICPD at Ten: Where are we now?, 2004 
68 UNAIDS, Report on the global AIDS epidemic, July 2004 
69 A response to HIV/AIDS inside the EU and in neighbouring countries is presented in the recently 
finalised Commission working paper “Coordinated and integrated approach to combat HIV/AIDS 
within the European Union and its neighbourhood” 
70 WHO, Report of the Commission on Macroeconomics and Health, December 2001,  
www3.who.int/whosis/cmh/cmh_report/e/report.cfm?path=cmh,cmh_report&language=english 
71 World Bank, The Long-Run Economic Costs of AIDS: Theory and an Application to South Africa, 
2003 
72 WHO, Macroeconomics and Health: Investing in Health for Economic Development. Report of the 
commission on Macroeconomics and Health, 20 December 2001 
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Human security and human rights as a complementary framework: For all three 
diseases, the impact goes far beyond the individual. The effects of HIV/AIDS in 
particular are now challenging the basic stability of countries. As the pandemic 
spreads in developing countries, its negative effects on the social, economic, and 
political fabric of communities grow. At societal level, HIV/AIDS is decimating 
communities and destroying social cohesion. In seven African countries where HIV 
prevalence is more than 20%, the average life expectancy of a person born between 
1995-2000 has declined from 62 to 49 years.73 The awareness of reduced life 
expectancy on such a high proportion of society has a traumatic effect on people’s 
minds, norms and behaviour. Although the disease is becoming more widespread, 
acceptance is not following suit, and stigma and discrimination against people living 
with HIV/AIDS still remains. Enforcement of harsh laws has the effect of 
marginalising and further stigmatising many people at greater risk of the diseases 
(e.g. commercial sex workers, injecting drug users, and men having sex with men). 
People whose human rights are abused are most vulnerable to HIV/AIDS. 
The potential relation between HIV/AIDS and political instability is gathering 
increased international attention. HIV/AIDS may have links to the breakdown of 
institutions, and has been shown to decimate many government sectors, such as 
education, health and the military. Whole cadres of skilled social service 
professionals (including those in the education and health sectors) are affected. In 
Zimbabwe, for example, it is estimated that by the end of 2003 30% of all teachers 
were HIV positive. This contributes to a vicious circle which makes it harder to 
confront HIV/AIDS. 
Gender dimension: The female face of the HIV/AIDS pandemic continues and 
grows; HIV/AIDS disproportionately affects women in terms of infection, impact 
and access to treatment. Women are more likely to be infected by HIV due to 
biological reasons but also due to inequalities in access to information, education, 
care, negotiation ability, societal and familial empowerment and condoms. 
HIV/AIDS is spreading rapidly among young girls and women, and women account 
for almost half of those already infected globally.74 (In Sub-Saharan Africa, the 
percentage is higher, with women comprising 56.7% of adults infected with HIV by 
the end of 200375). In terms of new infections, globally six out of ten new HIV 
infections occur in women. And in the young age group of 15-24, young women are 
more than three times as likely as young men to be infected.76 They are also more 
likely to be the main care-givers for those suffering from HIV/AIDS. Women bear a 
disproportionate burden of malaria. Pregnant women and their children are 
particularly vulnerable to malaria consequences (e.g. perinatal mortality, low birth 
weight and maternal anaemia). 
Age dimension: HIV/AIDS mostly kills people in the productive age. The legacy of 
orphans caused by parents dying from HIV/AIDS is shocking – there are 12 million 
                                                 
73 UNAIDS, Report on the global AIDS epidemic, July 2004 
74 UNAIDS, Report on the global AIDS epidemic, July 2004 
75 IPPF, ICPD at Ten: Where are we now?, 2004 
76 UNAIDS, UNFPA, UNIFEM, Women and HIV/AIDS: Confronting the Crisis, 2004 
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orphans in Africa alone, and it is estimated that there will be more than 18 million by 
the end of the decade.77 Many older women are now looking after young orphaned 
family members, and there is increased pressure on the transmission of cultures, 
norms of behaviour and simple societal survival mechanisms. Malaria causes 20% of 
childhood deaths in Africa, and the long-term consequences of malaria, for those 
who survive, include debilitating disabilities. 
5. CONCLUSIONS 
It may sound strange to talk about progress when there are still more than 6 million 
people in the world dying each year from HIV/AIDS, malaria and TB. The fact that 
these preventable diseases are still not under control should remain the main focus 
when the EC and the EU Member States set priorities for external action to confront 
the three diseases. 
Implementation of the policy framework (2000) and the PfA (2001) has seen major 
achievements, some of which need to be further accelerated. There have also been 
some issues where progress has been slow. These, and new evolving challenges, 
need to be addressed. Of particular significance in the achievements are:  
• Impact: A four-fold increase in EC resources allocated specifically to confronting 
the three diseases, with a €259.02 million annual average programmed for 2003-
2006 as compared to a €59.32 million annual average committed for 1994-2002 
(including a significant increase in research funds). 
• Affordability: A reduction by up to 98% in the price of some key pharmaceutical 
products in developing countries. 
• Research and development: The establishment of the European and Developing 
Countries Clinical Trials Partnership (EDCTP), which focuses on clinical trials for 
new interventions confronting the three diseases and on research-oriented capacity 
building, especially in sub-Saharan Africa. 
• Partnership: An active EC role in terms of leadership, coordinating positions and 
mobilising resources among the EU Member States and other donors. This 
includes a strong European voice in international fora on key issues, such as 
Trade-Related Aspects of Intellectual Property Rights (TRIPs) and the Cairo 
Agenda (ICPD). 
Outstanding challenges remain. The EC has allocated increased resources since the 
adoption of the PfA to confront the three diseases. However, EC resources allocated 
to health as a focal sector have decreased over time. Specific support for health 
systems, as well as for overall social services, needs to be prioritised by countries. 
It is difficult to monitor the health outcomes of macroeconomic budget support. The 
EC should work with EU Member States (particularly the ones that are also moving 
                                                 
77 UNAIDS, Report on the global AIDS epidemic, July 2004 
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towards macroeconomic budget support) to assess EC funding channels. The 
assessment will determine whether these channels allow for increased resource flows 
to the social sectors, and whether this translates into improved health outcomes. 
It is essential for countries to invest in ailing health infrastructure and other social 
services, and to strengthen the overburdened human resource capacity. This includes 
accelerated action on staff training, appropriate remuneration and retention of staff, 
and responsive management. This could also include innovative actions to help 
mitigate brain drain. To support this, the EC needs to ensure sustainable and long-
term financing, both at country and global levels through innovative actions and 
flexible instruments that permit an optimal use of resources and increased impact. 
The EC needs to support regulatory capacities in developing countries. In this 
context, the recently adopted revision of the EU pharmaceutical legislation enables 
the Community, in cooperation with WHO, to provide scientific assistance to non-
EU countries, for the evaluation of medicines that meet their own pubic health needs. 
To further increase affordability, the EC should focus on upholding the WTO TRIPs 
commitments. The EC needs to monitor the price of pharmaceutical products 
purchased by countries that receive EC funding for health or macroeconomic budget 
support, in an effort to increase price transparency. The EC should support a broader 
range of tiered price pharmaceutical products (including anti-retroviral second-line 
treatments, FDCs, and other products such as ACTs for malaria). Improving 
investments in health and other social services will also contribute to increasing 
access to affordable pharmaceutical products. 
Other challenges include the research and development of new tools such as AIDS 
vaccines and microbicides, both with EDCTP and other key partners. The EC should 
explore the issue of incentives for private enterprise. Further involving the private 
sector in the promotion of private investment, contributions to multilateral initiatives 
and mechanisms (such as the Global Fund) and in research (such as the EDCTP) 
remains a challenge. 
There is a continued need for cooperation with other partners, including third 
countries and civil society. Involving all these partners in an institutionalised 
Stakeholder Forum, as originally suggested in the PfA, remains important. The EC is 
in a unique position to promote efficiency and cooperate with EU Member States on 
sharing technical assistance in partner countries. Minimising the negative impact of 
numerous and sometimes divergent international initiatives through enhanced 
coordination, harmonisation and through global initiatives such as the Three Ones is 
important. 
Moving beyond the PfA, the EC needs to respond to evolving challenges. The 
diseases are spreading further geographically. The enlarged EU faces a re-emergence 
of TB (especially multi-drug resistant variants), and a rapidly rising incidence and 
prevalence of HIV/AIDS. This demands a strong EC/EU response. These diseases 
disproportionately affect women, so there is a need to fully consider patterns and 
causes of the dramatic increase in HIV/AIDS transmission to women. The diseases 
are also prominent in children, affecting them both directly and indirectly; 
consideration of the impact of the diseases on different ages is imperative. 
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The EC policy framework remains valid, with the focus on the three diseases, and the 
comprehensive policy mix of prevention, treatment and palliative care. Poverty 
reduction remains the key rationale for action on HIV/AIDS, malaria and TB. The 
increasingly obvious effects of HIV/AIDS on society, the economy, and government 
institutions also require the consideration of a complementary framework of human 
security and human rights. 
The EC will continue to act at both country and global levels. The simultaneous and 
coherent actions reinforce each other, and allow for increased effectiveness. This 
progress report has illustrated the value in allocating additional resources to countries 
faster and effectively through global instruments, for example through the Global 
Fund. There are also certain issues that can only be addressed at global level. The EC 
should therefore continue to play an important role in developing a common 
European response and advocating policy in international fora. The maintenance of 
international commitments, such as those made on sexual and reproductive health 
and rights and TRIPs, is paramount. The long-term vision of Europe and its partners 
remains the achievement of the MDGs. 
The synergy of different interlinking and mutually supporting actions on 
development, trade and research has created a larger impact. The EC should now 
build further on this strength. The need for policy coherence, both within the EC and 
across all partners, is stronger than ever within an increasingly diverse global 
institutional set-up. 
The moment is right for the EC to take stock of what has been achieved, reflect on 
what has changed, reinforce its commitments and build on existing momentum to 
shape key actions for the years to come. This will require identification of 
appropriate instruments, including the use of new financial instruments for EC 
external action and the 7th FP (RTD). An updated and comprehensive EC policy 
framework for confronting HIV/AIDS, malaria and TB globally will be presented in 
an EC Communication. 
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Annex 1: European Council and European Parliament Resolutions relating to 
the PfA 
Council of the European Union 
- Resolution on "Health and Poverty" of 30 May 2002, (Doc: 8958/02.) 
http://europa.eu.int/comm/development/body/theme/human_social/docs/health/02-
05_council_resolution.pdf#zoom=100 
- Resolution on “Programme for action: accelerated action on HIV/AIDS, malaria 
and tuberculosis in the context of poverty reduction” of 14 May 2001, (Doc: 
6802/01) 
http://register.consilium.eu.int/pdf/en/01/st08/08495en1.pdf 
- Resolution on “Communicable Diseases and Poverty” of 10 November 2000, (Doc: 
12929/00) 
http://register.consilium.eu.int/pdf/en/00/st12/12929en0.pdf 
- Conclusions on “Communicable diseases: HIV/AIDS, malaria and tuberculosis” of 
18 May 2000 
http://europa.eu.int/rapid/pressReleasesAction.do?reference=PRES/00/156&format=
HTML&aged=1&language=EN&guiLanguage=en 
European Parliament 
- Doc: PE 286.865/DEF or A5-0263/2001 
Report on the Commission communication on accelerated action targeted at major 
communicable diseases within the context of poverty reduction (COM(2000)585 – 
C5-0014/2001 - 2001/2006(COS)) - Committee on Development and Cooperation 
http://www2.europarl.eu.int/omk/sipade2?PUBREF=-
//EP//NONSGML+REPORT+A5-2001-
0263+0+DOC+PDF+V0//EN&L=EN&LEVEL=2&NAV=S&LSTDOC=Y 
- Doc: PE 310.468/DEF A5-0394/2002 
Report on the proposal for a European Parliament and Council regulation on aid for 
poverty diseases (HIV/AIDS, malaria and tuberculosis) in developing countries – 
Committee on Development and Cooperation 
http://www2.europarl.eu.int/omk/sipade2?PUBREF=-
//EP//NONSGML+REPORT+A5-2002-
0394+0+DOC+PDF+V0//EN&L=EN&LEVEL=2&NAV=S&LSTDOC=Y 
- Doc: PE 310.467/DEF A5-0020/2003 
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Report on the proposal for a European Parliament and Council regulation on aid for 
policies and actions on reproductive and sexual health and rights in developing 
countries – Committee on Development and Cooperation 
http://www2.europarl.eu.int/omk/sipade2?PUBREF=-
//EP//NONSGML+REPORT+A5-2003-
0020+0+DOC+PDF+V0//EN&L=EN&LEVEL=2&NAV=S&LSTDOC=Y 
- Doc: PE 310.512/DEF A5-0217/2003 
Report on the Commission communication on Health and Poverty Reduction in 
Developing Countries - Committee on Development and Cooperation 
http://www2.europarl.eu.int/omk/sipade2?PUBREF=-
//EP//NONSGML+REPORT+A5-2003-
0217+0+DOC+PDF+V0//EN&L=EN&LEVEL=2&NAV=S&LSTDOC=Y 
- Doc: PE 326.769/DEF A5-0474/2003 
Report on the Commission communication on the update of the EC Programme for 
Action: accelerated action on HIV/AIDS, malaria and tuberculosis in the context of 
poverty reduction; outstanding policy issues and future challenges – Committee on 
Development and Cooperation 
http://www2.europarl.eu.int/omk/sipade2?PUBREF=-
//EP//NONSGML+REPORT+A5-2003-
0474+0+DOC+PDF+V0//EN&L=EN&LEVEL=2&NAV=S&LSTDOC=Y 
- Doc: PE 326.776/DEF A5-0055/2004 
Report on population and development: 10 years after the UN Conference in Cairo – 
Committee on Development and Cooperation 
http://www2.europarl.eu.int/omk/sipade2?PUBREF=-
//EP//NONSGML+REPORT+A5-2004-
0055+0+DOC+PDF+V0//EN&L=EN&LEVEL=2&NAV=S&LSTDOC=Y 
ACP-EU Joint Parliamentary Assembly 
- RESOLUTION on poverty-related diseases and reproductive health in ACP States, 
in the context of the 9th EDF 
http://www.europarl.eu.int/intcoop/acp/60_07/pdf/resolution02_en.pdf 
- RESOLUTION on HIV/AIDS. The ACP-EU Joint Parliamentary Assembly, 
meeting in Brussels (Belgium), 29 October-1 November 2001 
http://europa.eu.int/eur-lex/pri/en/oj/dat/2002/c_078/c_07820020402en00220083.pdf 
- RESOLUTION on health issues, young people, the elderly and people living with 
disabilities. The ACP-EU Joint Parliamentary Assembly, meeting in Cape Town 
(South Africa), 18-21 March 2002 
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http://europa.eu.int/eur-lex/pri/en/oj/dat/2002/c_231/c_23120020927en00190066.pdf 
- RESOLUTION on the impact of communicable diseases on health, young people, 
the elderly and people living with disabilities. The ACP-EU Joint Parliamentary 
Assembly, meeting in Cape Town (South Africa), 18-21 March 2002 
http://europa.eu.int/eur-lex/pri/en/oj/dat/2002/c_231/c_23120020927en00190066.pdf 
- RESOLUTION on WTO negotiations on health issues. The ACP-EU Joint 
Parliamentary Assembly, meeting in Brazzaville (Republic of the Congo) from 31 
March to 3 April 2003 
http://www.europarl.eu.int/intcoop/acp/60_05/pdf/resolution_07_en.pdf 
- 2001 Genoa Summit. Genoa Plan for Africa, Genoa, 21 July, 2001 
http://www.g8.gc.ca/2001genoa/july-21-01-1-en.asp 
- 2002 Kananaskis Summit, 25-27 June, 2002, G8 AFRICA ACTION PLAN 
http://www.g8.gc.ca/2002Kananaskis/afraction-en.pdf 
- 2003 Evian Summit, 1-3 June 2003 
http://www.g8.gc.ca/health-en.asp 
- 2004 Sea Island Summit, 9-10 June Sea Island, G8 Action to Endorse and Establish 
a Global HIV Vaccine Enterprise 
http://www.g8.gc.ca/g8_vaccine-en.asp 
- EU-US Summit, Gothenburg Statement, 14 June 2001 
http://europa.eu.int/comm/external_relations/us/sum06_01/statement.htm 
- EU-US Declaration on HIV/AIDS, malaria and tuberculosis, Dromoland Castle, 26 
June 2004 
http://europa.eu.int/comm/external_relations/us/sum06_04/decl_hiv.pdf 
- Thessaloniki European Council, 19-20 June 2003: Presidency Conclusions 
http://www.eu2003.gr/en/articles/2003/6/20/3121/ 
- Draft EU Declaration on the International Conference on support to the Global 
Fund to fight HIV/AIDS, tuberculosis and malaria of 11 July 2003 – 11378/03 
http://europa.eu.int/comm/development/body/theme/human_social/docs/health/03-
07_draft_declaration_global_fund.pdf#zoom=100 
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Annex 2: Contributions by the EC and EU Member States to the Global Fund, 
the International Aids Vaccine Initiative, and the International Partnership for 
Microbicides 
It is difficult to compare bilateral funding of HIV/AIDS, malaria and TB across 
countries because of their different categorisation (some focusing on sectors, others 
on regions/countries, and others on diseases). The contribution of the EC and of EU 
Member States since 2001 to date to the Global Fund, IAVI and IPM provides one 
example of their funding. It should not be taken as indicative of other funding trends, 
and there are other research initiatives (such as AMANET and the European Malaria 
Vaccine Initiative) that receive support from Europe. 
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Table 3: Financial commitment to the Global Fund by the EC and EU Member 
States to date
78 
EC and EU 
Member States 
Amount 
contributed 
2001-2002 (in 
US$) 
Amount 
contributed 
2003 (in US$) 
Amount 
contributed so 
far, 2004 (in 
US$) 
Austria 1,075,900 - 13,827,500 
Belgium 12,207,409 7,229,938 10,270,518 
Denmark 14,816,511 13,790,866 16,188,433 
EC 137,064,385  50,360,226 264,413,350 
France 58,299,236 61,084,236 180,505,415 
Germany 11,955,200 37,427,325 45,944,850 
Hungary - - 10,000 
Ireland 9,835,000 11,161,430 12,299,000 
Italy 108,618,673 106,541,600 - 
Luxembourg 1,037,500 1,094,820 2,365,000 
Netherlands 8,087,400 43,590,360 47,886,680 
Poland - 20,000 - 
Portugal - 400,000 200,000 
Spain - 35,000,000 15,000,000 
Sweden 22,369,965 11,488,363 39,159,992 
UK 78,215,278 40,032,750 54,980,010 
TOTAL 463,622,457 384,221,914 622,815,249 
                                                 
78 From the Global Fund web-page, http://www.theglobalfund.org/en/ 
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Table 4: Financial commitment to the International AIDS Vaccine Initiative 
(IAVI) by the EC and EU Member States to date
79 
EC and EU 
Member States 
Amount 
contributed 
2002-2003 (in 
US$) 
Commitments 
2004-2007 (in 
US$) 
Total 
commitments 
(in US$) 
Denmark 3,358,525 1,617,646 4,976,171 
EC - 3,000,000 3,000,000 
Ireland 7,690,288 5,800,000 13,490,288 
Netherlands 25,117,124 15,600,000 40,717,124 
Sweden 359,812 197,910 557,722 
UK 14,339,741 9,000,000 23,339,741 
TOTAL 50,865,490 35,215,556 86,081,046 
Table 5: Financial commitment to the International Partnership for 
Microbicides (IPM) by the EC and EU Member States to date
80 
EC and EU 
Member States 
Amount 
contributed 
2002-2003 (in 
US$) 
Commitments 
2004-2007 (in 
US$) 
Total 
commitments 
(in US$) 
Denmark 774,355 - 774,355 
EC - - - 
Ireland 3,812,250 3,048,250 6,860,500 
Netherlands 2,325,100 7,315,800 9,640,900 
UK 987,962 1,070,670 2,058,632 
TOTAL 7,899,667 11,434,720 19,334,387 
                                                 
79 Data received from IAVI (September 2004) 
80 Data received from IPM (September 2004) 
 EN 52   EN 
Annex 3: Some illustrative prices of ARVs published on the Global Fund’s web-
page 
The Price Reporting Mechanism is available at: 
www.theglobalfund.org/en/funds_raised/price_reporting/default.asp. 
At present, visitors to the website can see the prices paid by 17 countries in 128 
purchases of anti-retroviral drugs costing a total of US$4.8 million. Examples of 
prices paid include: 
• Five countries purchasing 400mg doses of Indinavir between August 2003 and 
July 2004 paid between US$0.25 and US$0.30 per dose when purchasing from 
two different manufacturers in India, and paid US$0.28 per dose when purchasing 
from one manufacturer in the United States. 
• Eight countries purchasing 200mg doses of Nevirapine between August 2003 and 
July 2004 paid between US$0.11 and US$0.36 per dose when purchasing from 
four different manufacturers in India and Cuba, and paid US$3.43 per dose when 
purchasing from one manufacturer in the United States. 
The existence of the Mechanism produces several benefits.81 First, countries that are 
preparing Global Fund proposals can develop a better sense of how much to budget 
for product procurement. Second, grant recipients who are negotiating procurement 
contracts with vendors can do so from a strengthened position as a result of knowing 
what others have paid. Third, grant recipients will be less tempted to enter into 
contracts on poor terms that have secret kick-back provisions (so long as they are 
required to report full details of their purchases). Finally, all stakeholders can be 
better informed on how Global Fund money is being used. 
                                                 
81 Other sources of price data include Sources and Prices of Selected Medicines and Diagnostics for 
People Living with HIV/AIDS, which is available on the following website: http://www.accessmed-
msf.org 
